US7208600B2 - Inhibitors of serine proteases, particularly HCV NS3-NS4A proteases - Google Patents
Inhibitors of serine proteases, particularly HCV NS3-NS4A proteases Download PDFInfo
- Publication number
- US7208600B2 US7208600B2 US10/964,214 US96421404A US7208600B2 US 7208600 B2 US7208600 B2 US 7208600B2 US 96421404 A US96421404 A US 96421404A US 7208600 B2 US7208600 B2 US 7208600B2
- Authority
- US
- United States
- Prior art keywords
- formula
- compounds
- aliphatic
- ring
- hcv
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related, expires
Links
- 0 [10*]C([10*])(NS([10*])(=O)=O)C(C)(C)C.[10*]C([10*])(O)C(C)(C)C.[10*]C([10*])(S)C(C)(C)C.[10*]S(=O)NC([10*])([10*])C(C)(C)C.[10*][K]C(=O)NC([10*])(CNS(=O)(=O)[K][10*])C(C)(C)C.[10*][K]C(=O)NC([10*])(CNS(=O)[K][10*])C(C)(C)C.[10*][K]C(=O)NC([10*])([10*])C(C)(C)C.[10*][K]C(=O)NCC([10*])(NC(=O)[K][10*])C(C)(C)C.[10*][K]C(=O)NCC([10*])(NS(=O)(=O)[K][10*])C(C)(C)C.[10*][K]C(=O)NCC([10*])(NS(=O)[K][10*])C(C)(C)C.[10*][K]S(=O)(=O)NCC([10*])(NS(=O)(=O)[K][10*])C(C)(C)C.[10*][K]S(=O)NCC([10*])(NS(=O)[K][10*])C(C)(C)C Chemical compound [10*]C([10*])(NS([10*])(=O)=O)C(C)(C)C.[10*]C([10*])(O)C(C)(C)C.[10*]C([10*])(S)C(C)(C)C.[10*]S(=O)NC([10*])([10*])C(C)(C)C.[10*][K]C(=O)NC([10*])(CNS(=O)(=O)[K][10*])C(C)(C)C.[10*][K]C(=O)NC([10*])(CNS(=O)[K][10*])C(C)(C)C.[10*][K]C(=O)NC([10*])([10*])C(C)(C)C.[10*][K]C(=O)NCC([10*])(NC(=O)[K][10*])C(C)(C)C.[10*][K]C(=O)NCC([10*])(NS(=O)(=O)[K][10*])C(C)(C)C.[10*][K]C(=O)NCC([10*])(NS(=O)[K][10*])C(C)(C)C.[10*][K]S(=O)(=O)NCC([10*])(NS(=O)(=O)[K][10*])C(C)(C)C.[10*][K]S(=O)NCC([10*])(NS(=O)[K][10*])C(C)(C)C 0.000 description 40
- HVUVDXDWZFTAHL-UHFFFAOYSA-N CC(C)(C)C(C)(C)C.CC(C)(C)C(C1=CC=CC=C1)C1=CC=CC=C1.CC(C)(C)C1=CC=CC=C1.CC(C)(C)C1CCCCC1.CC(C)(C)CC(C)(C)C.CC(C)(C)CC1=CC=CC=C1.CC(C)(C)CC1CCCCC1.CC(C)C(C)(C)C.CC(C)CC(C)(C)C.CC(C1=CC=CC=C1)C(C)(C)C.CC1=C(CC(C)(C)C)C=CC=C1 Chemical compound CC(C)(C)C(C)(C)C.CC(C)(C)C(C1=CC=CC=C1)C1=CC=CC=C1.CC(C)(C)C1=CC=CC=C1.CC(C)(C)C1CCCCC1.CC(C)(C)CC(C)(C)C.CC(C)(C)CC1=CC=CC=C1.CC(C)(C)CC1CCCCC1.CC(C)C(C)(C)C.CC(C)CC(C)(C)C.CC(C1=CC=CC=C1)C(C)(C)C.CC1=C(CC(C)(C)C)C=CC=C1 HVUVDXDWZFTAHL-UHFFFAOYSA-N 0.000 description 2
- AGIFYIDKYVYQLW-UHFFFAOYSA-N CC(C)(C)C(C)(C)C.CC(C)(C)C1CC2=C(C=CC=C2)C1.CC(C)(C)C1CCC2=C1C=CC=C2.CC(C)(C)C1CCCC1.CC(C)(C)C1CCCCC1.CC(C)(C)CC(C)(C)C.CC(C)(C)CCC(=O)O.CC(C)C(C)(C)C.CCC(C)C(C)(C)C Chemical compound CC(C)(C)C(C)(C)C.CC(C)(C)C1CC2=C(C=CC=C2)C1.CC(C)(C)C1CCC2=C1C=CC=C2.CC(C)(C)C1CCCC1.CC(C)(C)C1CCCCC1.CC(C)(C)CC(C)(C)C.CC(C)(C)CCC(=O)O.CC(C)C(C)(C)C.CCC(C)C(C)(C)C AGIFYIDKYVYQLW-UHFFFAOYSA-N 0.000 description 2
- PFYDMJJFOUKMNW-UHFFFAOYSA-N [H]N1C(=O)CC(=O)C1C(C)(C)C.[H]N1C(=O)CS(=O)(=O)C1C(C)(C)C.[H]N1C(=O)CS(=O)(=O)cc1C(C)(C)C.[H]N1C(=O)CS(=O)(=O)cc1C(C)(C)C.[H]N1C(=O)CS(=O)C1C(C)(C)C.[H]N1C(=O)CS(=O)cc1C(C)(C)C.[H]N1C(=O)CS(=O)cc1C(C)(C)C.[H]N1C(=O)Ccc1C(C)(C)C.[H]N1C(C(C)(C)C)C(=O)CS1(=O)=O.[H]N1C(C(C)(C)C)C(=O)CS1=O.[H]N1c(C(C)(C)C)cC(=O)CS1(=O)=O.[H]N1c(C(C)(C)C)cCS1(=O)=O.[H]N1c(C(C)(C)C)cCS1=O Chemical compound [H]N1C(=O)CC(=O)C1C(C)(C)C.[H]N1C(=O)CS(=O)(=O)C1C(C)(C)C.[H]N1C(=O)CS(=O)(=O)cc1C(C)(C)C.[H]N1C(=O)CS(=O)(=O)cc1C(C)(C)C.[H]N1C(=O)CS(=O)C1C(C)(C)C.[H]N1C(=O)CS(=O)cc1C(C)(C)C.[H]N1C(=O)CS(=O)cc1C(C)(C)C.[H]N1C(=O)Ccc1C(C)(C)C.[H]N1C(C(C)(C)C)C(=O)CS1(=O)=O.[H]N1C(C(C)(C)C)C(=O)CS1=O.[H]N1c(C(C)(C)C)cC(=O)CS1(=O)=O.[H]N1c(C(C)(C)C)cCS1(=O)=O.[H]N1c(C(C)(C)C)cCS1=O PFYDMJJFOUKMNW-UHFFFAOYSA-N 0.000 description 2
- HKTUMRPSWBRPLM-UHFFFAOYSA-N B.B.B.B.B.B.B.B.B.B.B.B.B.B.CC(=O)C1CCCCN1C.CC(=O)C1CCCCN1C.CC(=O)C1CCCCN1C.CC(=O)C1CCCCN1C.CC(=O)C1CCCN1C.CC(=O)C1CCCN1C.CC(=O)C1CCCN1C.CC(=O)C1CCCN1C.CC(=O)C1CCCN1C.CC(=O)C1CCCN1C.CC(=O)C1CCCN1C Chemical compound B.B.B.B.B.B.B.B.B.B.B.B.B.B.CC(=O)C1CCCCN1C.CC(=O)C1CCCCN1C.CC(=O)C1CCCCN1C.CC(=O)C1CCCCN1C.CC(=O)C1CCCN1C.CC(=O)C1CCCN1C.CC(=O)C1CCCN1C.CC(=O)C1CCCN1C.CC(=O)C1CCCN1C.CC(=O)C1CCCN1C.CC(=O)C1CCCN1C HKTUMRPSWBRPLM-UHFFFAOYSA-N 0.000 description 1
- NXCBLVVDTVXJCS-UHFFFAOYSA-N B.B.CC(=O)C1CCCN1.CC(=O)C1CCCN1 Chemical compound B.B.CC(=O)C1CCCN1.CC(=O)C1CCCN1 NXCBLVVDTVXJCS-UHFFFAOYSA-N 0.000 description 1
- CVWRJRVTGIKACK-UHFFFAOYSA-N C#CCC(C)(C)C.C=CCC(C)(C)C.CC(C)(C)C1=CC=CC=C1.CC(C)(C)CC(F)(F)F.CC(C)(C)CC(F)F.CC(C)(C)CCC(F)(F)F.CC(C)(C)CCC(F)F.CC(C)(C)CS.CCC(C)(C)C.CCCC(C)(C)C Chemical compound C#CCC(C)(C)C.C=CCC(C)(C)C.CC(C)(C)C1=CC=CC=C1.CC(C)(C)CC(F)(F)F.CC(C)(C)CC(F)F.CC(C)(C)CCC(F)(F)F.CC(C)(C)CCC(F)F.CC(C)(C)CS.CCC(C)(C)C.CCCC(C)(C)C CVWRJRVTGIKACK-UHFFFAOYSA-N 0.000 description 1
- OMHRVJFPGLSMSK-YNGUASKFSA-N C.CC(=O)O.CCO(C)CC.COC(=O)[C@@H]1CC(=O)CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)OC(C)(C)C)C1CCCCC1)C(C)(C)C.COC(=O)[C@@H]1CC(O)CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)OC(C)(C)C)C1CCCCC1)C(C)(C)C.COC(=O)[C@@H]1CC2(CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=CN=CC=N1)C1CCCCC1)C(C)(C)C)SCCCS2.COC(=O)[C@@H]1CC2(CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)OC(C)(C)C)C1CCCCC1)C(C)(C)C)SCCCS2.ClCCl Chemical compound C.CC(=O)O.CCO(C)CC.COC(=O)[C@@H]1CC(=O)CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)OC(C)(C)C)C1CCCCC1)C(C)(C)C.COC(=O)[C@@H]1CC(O)CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)OC(C)(C)C)C1CCCCC1)C(C)(C)C.COC(=O)[C@@H]1CC2(CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=CN=CC=N1)C1CCCCC1)C(C)(C)C)SCCCS2.COC(=O)[C@@H]1CC2(CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)OC(C)(C)C)C1CCCCC1)C(C)(C)C)SCCCS2.ClCCl OMHRVJFPGLSMSK-YNGUASKFSA-N 0.000 description 1
- PFDVUMIFYZCPBJ-UHFFFAOYSA-N C.O=C(O)C1CC2CCCCC2N1.O=C1CCC2CCCCC2N1.O=C1NC2CCCCC2CC1Cl Chemical compound C.O=C(O)C1CC2CCCCC2N1.O=C1CCC2CCCCC2N1.O=C1NC2CCCCC2CC1Cl PFDVUMIFYZCPBJ-UHFFFAOYSA-N 0.000 description 1
- RCLXUNZKWBLZFG-UHFFFAOYSA-L C1=CCCCC1.C=C(Cl)C#N.CC(=O)N1C(C#N)CC2CCCCC21.CC(=O)NC1CCCCC1CC(Cl)C#N.CC(=O)NC1CCCCC1[Hg]Cl.CC(C)(C)OC(=O)N1C(C(=O)O)CC2CCCCC21.O=BC#CO.O=C(O)C1CC2CCCCC2N1.[Na]Cl Chemical compound C1=CCCCC1.C=C(Cl)C#N.CC(=O)N1C(C#N)CC2CCCCC21.CC(=O)NC1CCCCC1CC(Cl)C#N.CC(=O)NC1CCCCC1[Hg]Cl.CC(C)(C)OC(=O)N1C(C(=O)O)CC2CCCCC21.O=BC#CO.O=C(O)C1CC2CCCCC2N1.[Na]Cl RCLXUNZKWBLZFG-UHFFFAOYSA-L 0.000 description 1
- NAFZDOTWXGXUHH-UHFFFAOYSA-N C=C(C(C)NC)N1CSCC1C(C)=O.CCC(NC)C(=O)N1COCCC1C(C)=O.CNC1CCC2CNCC(C(C)=O)N2C1=O.CNC1CCC2COCC(C(C)=O)N2C1=O.CNC1CCC2CSCC(C(C)=O)N2C1=O.CNC1CCC2NCCC(C(C)=O)N2C1=O.CNC1CCC2OCCC(C(C)=O)N2C1=O.CNC1CCC2SCCC(C(C)=O)N2C1=O.CNC1CCCC2CCC(C(C)=O)N2C1=O.CNC1CCCC2CCCC(C(C)=O)N2C1=O.CNC1CCCC2COCC(C(C)=O)N2C1=O.CNC1CCCC2CSCC(C(C)=O)N2C1=O.CNC1CCCC2NCC(C(C)=O)N2C1=O.CNC1CCCC2NCCC(C(C)=O)N2C1=O.CNC1CCCC2OCC(C(C)=O)N2C1=O.CNC1CCCC2SCCC(C(C)=O)N2C1=O Chemical compound C=C(C(C)NC)N1CSCC1C(C)=O.CCC(NC)C(=O)N1COCCC1C(C)=O.CNC1CCC2CNCC(C(C)=O)N2C1=O.CNC1CCC2COCC(C(C)=O)N2C1=O.CNC1CCC2CSCC(C(C)=O)N2C1=O.CNC1CCC2NCCC(C(C)=O)N2C1=O.CNC1CCC2OCCC(C(C)=O)N2C1=O.CNC1CCC2SCCC(C(C)=O)N2C1=O.CNC1CCCC2CCC(C(C)=O)N2C1=O.CNC1CCCC2CCCC(C(C)=O)N2C1=O.CNC1CCCC2COCC(C(C)=O)N2C1=O.CNC1CCCC2CSCC(C(C)=O)N2C1=O.CNC1CCCC2NCC(C(C)=O)N2C1=O.CNC1CCCC2NCCC(C(C)=O)N2C1=O.CNC1CCCC2OCC(C(C)=O)N2C1=O.CNC1CCCC2SCCC(C(C)=O)N2C1=O NAFZDOTWXGXUHH-UHFFFAOYSA-N 0.000 description 1
- IJAUQBOIUHKWOW-UHFFFAOYSA-N C=CC1CC1(C)C.CC1(C)CC1C1CC1.CC1CC1(C)C.CCC1CC1(C)C.CCCC(C)(C)C.CCCC(C)(C)CC.CCCC(C)(C)CCC Chemical compound C=CC1CC1(C)C.CC1(C)CC1C1CC1.CC1CC1(C)C.CCC1CC1(C)C.CCCC(C)(C)C.CCCC(C)(C)CC.CCCC(C)(C)CCC IJAUQBOIUHKWOW-UHFFFAOYSA-N 0.000 description 1
- IFZLWCKHHRIMPS-UHFFFAOYSA-N C=CCC1CCN(C)C1C(C)=O.CC(=O)C1C(C(C)C)CCN1C.CC(=O)C1C(C)CCN1C.CC(=O)C1C(C2=CC=CC=C2)CCN1C.CC(=O)C1C(C2CCCCC2)CCN1C.CC(=O)C1CC(C#N)CN1C.CC(=O)C1CC(C)CN1C.CC(=O)C1CC(C2=CC=CC=C2)CN1C.CC(=O)C1CC(C2=CC=CC=C2)CN1C.CC(=O)C1CC(OC(=O)C2=CC3=C(C=CC=C3)C=C2)CN1C.CC(=O)C1CC(OC(=O)N2CCC3=C(C=CC=C3)C2)CN1C.CC(=O)C1CC(OC2=CC=CC=C2)CN1C.CCC(C)C1CCN(C)C1C(C)=O.CCC1CC(C(C)=O)N(C)C1.CCC1CCN(C)C1C(C)=O Chemical compound C=CCC1CCN(C)C1C(C)=O.CC(=O)C1C(C(C)C)CCN1C.CC(=O)C1C(C)CCN1C.CC(=O)C1C(C2=CC=CC=C2)CCN1C.CC(=O)C1C(C2CCCCC2)CCN1C.CC(=O)C1CC(C#N)CN1C.CC(=O)C1CC(C)CN1C.CC(=O)C1CC(C2=CC=CC=C2)CN1C.CC(=O)C1CC(C2=CC=CC=C2)CN1C.CC(=O)C1CC(OC(=O)C2=CC3=C(C=CC=C3)C=C2)CN1C.CC(=O)C1CC(OC(=O)N2CCC3=C(C=CC=C3)C2)CN1C.CC(=O)C1CC(OC2=CC=CC=C2)CN1C.CCC(C)C1CCN(C)C1C(C)=O.CCC1CC(C(C)=O)N(C)C1.CCC1CCN(C)C1C(C)=O IFZLWCKHHRIMPS-UHFFFAOYSA-N 0.000 description 1
- XDVSZNAFEADFSX-UHFFFAOYSA-N C=CCCCCC=O.CC(C)(C)OC(=O)N1C(C(=O)O)CC2CCCCC21.NC(CO)C1=CC=CC=C1.O=BC#CO.O=C(CBr)OC1=CC=CC=C1.O=C(O)C1CC2CCCCC2N1.O=C1CNC(C2=CC=CC=C2)CO1.O=C1OCC(C2=CC=CC=C2)N2C1CC1CCCCC12 Chemical compound C=CCCCCC=O.CC(C)(C)OC(=O)N1C(C(=O)O)CC2CCCCC21.NC(CO)C1=CC=CC=C1.O=BC#CO.O=C(CBr)OC1=CC=CC=C1.O=C(O)C1CC2CCCCC2N1.O=C1CNC(C2=CC=CC=C2)CO1.O=C1OCC(C2=CC=CC=C2)N2C1CC1CCCCC12 XDVSZNAFEADFSX-UHFFFAOYSA-N 0.000 description 1
- MYIDXARPGCMLOJ-UHFFFAOYSA-N C=CCOC1=CC=CC=C1C=O.CC(=O)C1CC2COC3=C(C=CC=C3)C2N1C(=O)OC(C)(C)C.CCOC(=O)C1CC2COC3=C(C=CC=C3)C2N1CC1=CC=CC=C1.CCOC(=O)CCNCC1=CC=CC=C1 Chemical compound C=CCOC1=CC=CC=C1C=O.CC(=O)C1CC2COC3=C(C=CC=C3)C2N1C(=O)OC(C)(C)C.CCOC(=O)C1CC2COC3=C(C=CC=C3)C2N1CC1=CC=CC=C1.CCOC(=O)CCNCC1=CC=CC=C1 MYIDXARPGCMLOJ-UHFFFAOYSA-N 0.000 description 1
- NSSNPFOVKPFFMY-UHFFFAOYSA-N CC(=O)C12C(C)C(C3CCCC31)N2C.CC(=O)C1C2C3CCC(C3)C2CN1C.CC(=O)C1C2CC2CN1C.CC(=O)C1C2CCC(C2)N1C.CC(=O)C1C2CCC(CC2)N1C.CC(=O)C1C2CCCCC2CN1C.CC(=O)C1CC2=C(C=CC=C2)CN1C.CC(=O)C1CC2=C(C=CC=C2)N1C.CC(=O)C1CC2C3=C(C=CC=C3)NC2N1C.CC(=O)C1CC2C3CCCCC3NC2N1C.CC(=O)C1CC2CC2N1C.CC(=O)C1CC2CCCC2N1C.CC(=O)C1CC2CCCCC2N1C Chemical compound CC(=O)C12C(C)C(C3CCCC31)N2C.CC(=O)C1C2C3CCC(C3)C2CN1C.CC(=O)C1C2CC2CN1C.CC(=O)C1C2CCC(C2)N1C.CC(=O)C1C2CCC(CC2)N1C.CC(=O)C1C2CCCCC2CN1C.CC(=O)C1CC2=C(C=CC=C2)CN1C.CC(=O)C1CC2=C(C=CC=C2)N1C.CC(=O)C1CC2C3=C(C=CC=C3)NC2N1C.CC(=O)C1CC2C3CCCCC3NC2N1C.CC(=O)C1CC2CC2N1C.CC(=O)C1CC2CCCC2N1C.CC(=O)C1CC2CCCCC2N1C NSSNPFOVKPFFMY-UHFFFAOYSA-N 0.000 description 1
- PJYMOHVQGRZSRZ-UHFFFAOYSA-K CC(=O)C1=C(C(=O)O)NC2=CC=CC=C21.CC(=O)C1=CC=C2NC(C(=O)O)=CC2=C1.CCOC(=O)C1=C(C(C)=O)C2=CC=CC=C2N1.CCOC(=O)C1=CC2=CC(C(C)=O)=CC=C2N1.CCOC(=O)C1=CC2=CC=CC=C2N1.Cl[Al](Cl)Cl Chemical compound CC(=O)C1=C(C(=O)O)NC2=CC=CC=C21.CC(=O)C1=CC=C2NC(C(=O)O)=CC2=C1.CCOC(=O)C1=C(C(C)=O)C2=CC=CC=C2N1.CCOC(=O)C1=CC2=CC(C(C)=O)=CC=C2N1.CCOC(=O)C1=CC2=CC=CC=C2N1.Cl[Al](Cl)Cl PJYMOHVQGRZSRZ-UHFFFAOYSA-K 0.000 description 1
- XUBFQGJPUWBMGB-UHFFFAOYSA-N CC(=O)C1=C(C(C)(C)C)NC(C)=C1C Chemical compound CC(=O)C1=C(C(C)(C)C)NC(C)=C1C XUBFQGJPUWBMGB-UHFFFAOYSA-N 0.000 description 1
- WQIOHEFBSZMOPN-UHFFFAOYSA-N CC(=O)C1C(C)C(C)CN1C.CC(=O)C1C(C)CC(C)N1C.CC(=O)C1C(C)CCN1C.CC(=O)C1CC(C)C(C)N1C.CC(=O)C1CC(C)CN1C.CC(=O)C1CCC(C)N1C Chemical compound CC(=O)C1C(C)C(C)CN1C.CC(=O)C1C(C)CC(C)N1C.CC(=O)C1C(C)CCN1C.CC(=O)C1CC(C)C(C)N1C.CC(=O)C1CC(C)CN1C.CC(=O)C1CCC(C)N1C WQIOHEFBSZMOPN-UHFFFAOYSA-N 0.000 description 1
- IWUKWGWRBXQJFE-UHFFFAOYSA-N CC(=O)C1C(C)C(C)CN1C.CC(=O)C1CC(OC2=C3C=CC=CC3=CC=C2)CN1C.CC(=O)C1CC(OC2=C3CC=CCC3=NC=N2)CN1C.CC(=O)C1CC(OC2=CC3=C(C=CC=C3)C=C2)CN1C.CC(=O)C1CC(OC2=CC=C(Cl)C=N2)CN1C.CC(=O)C1CCC(C)N1C.CC(=O)C1CCC(C2=CC=CC=C2)N1C.CC(=O)C1CCC(C2CCCCC2)N1C.CCC1C(C)CN(C)C1C(C)=O.CCC1CN(C)C(C(C)=O)C1C Chemical compound CC(=O)C1C(C)C(C)CN1C.CC(=O)C1CC(OC2=C3C=CC=CC3=CC=C2)CN1C.CC(=O)C1CC(OC2=C3CC=CCC3=NC=N2)CN1C.CC(=O)C1CC(OC2=CC3=C(C=CC=C3)C=C2)CN1C.CC(=O)C1CC(OC2=CC=C(Cl)C=N2)CN1C.CC(=O)C1CCC(C)N1C.CC(=O)C1CCC(C2=CC=CC=C2)N1C.CC(=O)C1CCC(C2CCCCC2)N1C.CCC1C(C)CN(C)C1C(C)=O.CCC1CN(C)C(C(C)=O)C1C IWUKWGWRBXQJFE-UHFFFAOYSA-N 0.000 description 1
- WYMINOMSSDVQKY-UHFFFAOYSA-N CC(=O)C1C2=C(C=CC=C2)CCN1C.CC(=O)C1C2=C(C=CC=C2)CN1C.CC(=O)C1CC2=C(C=CC=C2)CN1C.CC(=O)C1CCC2=C(/C=C\C=C/2)N1C.CC(=O)C1CCC2CC2N1C.CC(=O)C1CCC2CCC2N1C.CC(=O)C1CCC2CCCC2N1C.CC(=O)C1CCC2CNCC2N1C.CC(=O)C1CCC2COCC2N1C.CC(=O)C1CCC2CSCC2N1C.CC(=O)C1COC2CCCC2N1C.CC(=O)C1COC2CNCC2N1C.CC(=O)C1COC2COCC2N1C.CC(=O)C1COC2CSCC2N1C.CC(=O)C1CSC2CCCC2N1C.CC(=O)C1CSC2CNCC2N1C.CC(=O)C1CSC2COCC2N1C.CC(=O)C1CSC2CSCC2N1C Chemical compound CC(=O)C1C2=C(C=CC=C2)CCN1C.CC(=O)C1C2=C(C=CC=C2)CN1C.CC(=O)C1CC2=C(C=CC=C2)CN1C.CC(=O)C1CCC2=C(/C=C\C=C/2)N1C.CC(=O)C1CCC2CC2N1C.CC(=O)C1CCC2CCC2N1C.CC(=O)C1CCC2CCCC2N1C.CC(=O)C1CCC2CNCC2N1C.CC(=O)C1CCC2COCC2N1C.CC(=O)C1CCC2CSCC2N1C.CC(=O)C1COC2CCCC2N1C.CC(=O)C1COC2CNCC2N1C.CC(=O)C1COC2COCC2N1C.CC(=O)C1COC2CSCC2N1C.CC(=O)C1CSC2CCCC2N1C.CC(=O)C1CSC2CNCC2N1C.CC(=O)C1CSC2COCC2N1C.CC(=O)C1CSC2CSCC2N1C WYMINOMSSDVQKY-UHFFFAOYSA-N 0.000 description 1
- FLWMCISGMMCGGD-UHFFFAOYSA-N CC(=O)C1C2=C(C=CC=N2)CCN1C.CC(=O)C1C2=C(C=CN=C2)CCN1C.CC(=O)C1C2=C(C=NC=C2)CCN1C.CC(=O)C1C2=C(CCN1C)N=CC=C2.CC(=O)C1CC2=C(C=CC=N2)CN1C.CC(=O)C1CC2=C(C=CN=C2)CN1C.CC(=O)C1CC2=C(C=NC=C2)CN1C.CC(=O)C1CC2=C(CN1C)N=CC=C2.CC(=O)C1CNC2=C(C=CC=N2)N1C.CC(=O)C1CNC2=C(C=CN=C2)N1C.CC(=O)C1CNC2=C(C=NC=C2)N1C.CC(=O)C1CNC2=C(N=CC=C2)N1C Chemical compound CC(=O)C1C2=C(C=CC=N2)CCN1C.CC(=O)C1C2=C(C=CN=C2)CCN1C.CC(=O)C1C2=C(C=NC=C2)CCN1C.CC(=O)C1C2=C(CCN1C)N=CC=C2.CC(=O)C1CC2=C(C=CC=N2)CN1C.CC(=O)C1CC2=C(C=CN=C2)CN1C.CC(=O)C1CC2=C(C=NC=C2)CN1C.CC(=O)C1CC2=C(CN1C)N=CC=C2.CC(=O)C1CNC2=C(C=CC=N2)N1C.CC(=O)C1CNC2=C(C=CN=C2)N1C.CC(=O)C1CNC2=C(C=NC=C2)N1C.CC(=O)C1CNC2=C(N=CC=C2)N1C FLWMCISGMMCGGD-UHFFFAOYSA-N 0.000 description 1
- FCISLEXDGLTEGW-UHFFFAOYSA-N CC(=O)C1C2=C(C=CC=N2)CN1C.CC(=O)C1C2=C(C=CN=C2)CN1C.CC(=O)C1C2=C(C=NC=C2)CN1C.CC(=O)C1C2=C(CN1C)N=CC=C2.CC(=O)C1C2C=NOC2CN1C.CC(=O)C1C2CN=NC2CN1C.CC(=O)C1C2CNNC2CN1C.CC(=O)C1C2CNOC2CN1C.CC(=O)C1C2N=NCC2CN1C.CC(=O)C1C2NNCC2CN1C.CC(=O)C1C2ONCC2CN1C.CC(=O)C1CCC2=C(C=CC=N2)N1C.CC(=O)C1CCC2=C(C=CN=C2)N1C.CC(=O)C1CCC2=C(C=NC=C2)N1C.CC(=O)C1CCC2=C(N=CC=C2)N1C.CC(=O)C1COC2=C(C=CC=N2)N1C.CC(=O)C1COC2=C(C=CN=C2)N1C.CC(=O)C1COC2=C(C=NC=C2)N1C.CC(=O)C1COC2=C(N=CC=C2)N1C.CC(=O)C1CSC2=C(C=CC=N2)N1C.CC(=O)C1CSC2=C(C=CN=C2)N1C.CC(=O)C1CSC2=C(C=NC=C2)N1C.CC(=O)C1CSC2=C(N=CC=C2)N1C.CC(=O)C1NCC2C=NOC21 Chemical compound CC(=O)C1C2=C(C=CC=N2)CN1C.CC(=O)C1C2=C(C=CN=C2)CN1C.CC(=O)C1C2=C(C=NC=C2)CN1C.CC(=O)C1C2=C(CN1C)N=CC=C2.CC(=O)C1C2C=NOC2CN1C.CC(=O)C1C2CN=NC2CN1C.CC(=O)C1C2CNNC2CN1C.CC(=O)C1C2CNOC2CN1C.CC(=O)C1C2N=NCC2CN1C.CC(=O)C1C2NNCC2CN1C.CC(=O)C1C2ONCC2CN1C.CC(=O)C1CCC2=C(C=CC=N2)N1C.CC(=O)C1CCC2=C(C=CN=C2)N1C.CC(=O)C1CCC2=C(C=NC=C2)N1C.CC(=O)C1CCC2=C(N=CC=C2)N1C.CC(=O)C1COC2=C(C=CC=N2)N1C.CC(=O)C1COC2=C(C=CN=C2)N1C.CC(=O)C1COC2=C(C=NC=C2)N1C.CC(=O)C1COC2=C(N=CC=C2)N1C.CC(=O)C1CSC2=C(C=CC=N2)N1C.CC(=O)C1CSC2=C(C=CN=C2)N1C.CC(=O)C1CSC2=C(C=NC=C2)N1C.CC(=O)C1CSC2=C(N=CC=C2)N1C.CC(=O)C1NCC2C=NOC21 FCISLEXDGLTEGW-UHFFFAOYSA-N 0.000 description 1
- LCPNHGGGXJJKSX-UHFFFAOYSA-N CC(=O)C1C2C3CCC(C3)C2CN1C.CC(=O)C1C2C3CCC(N3)C2CN1C.CC(=O)C1C2C3CCC(O3)C2CN1C.CC(=O)C1C2C3CCC(S3)C2CN1C.CC(=O)C1C2CNCCC2CN1C.CC(=O)C1C2COCCC2CN1C.CC(=O)C1C2CSCCC2CN1C.CC(=O)C1C2NCCCC2CN1C.CC(=O)C1C2OCCCC2CN1C.CC(=O)C1C2SCCCC2CN1C Chemical compound CC(=O)C1C2C3CCC(C3)C2CN1C.CC(=O)C1C2C3CCC(N3)C2CN1C.CC(=O)C1C2C3CCC(O3)C2CN1C.CC(=O)C1C2C3CCC(S3)C2CN1C.CC(=O)C1C2CNCCC2CN1C.CC(=O)C1C2COCCC2CN1C.CC(=O)C1C2CSCCC2CN1C.CC(=O)C1C2NCCCC2CN1C.CC(=O)C1C2OCCCC2CN1C.CC(=O)C1C2SCCCC2CN1C LCPNHGGGXJJKSX-UHFFFAOYSA-N 0.000 description 1
- CGGZQWXCRCDELY-UHFFFAOYSA-N CC(=O)C1C2C=CC(C2)N1C.CC(=O)C1C2C=CC(CC2)N1C.CC(=O)C1C2C=CC(CN2)N1C.CC(=O)C1C2C=CC(CO2)N1C.CC(=O)C1C2C=CC(CS2)N1C.CC(=O)C1C2C=CC(N2)N1C.CC(=O)C1C2C=CC(NC2)N1C.CC(=O)C1C2C=CC(O2)N1C.CC(=O)C1C2C=CC(OC2)N1C.CC(=O)C1C2C=CC(S2)N1C.CC(=O)C1C2C=CC(SC2)N1C.CC(=O)C1C2CCC(C2)N1C.CC(=O)C1C2CCC(CC2)N1C.CC(=O)C1C2CCC(CN2)N1C.CC(=O)C1C2CCC(CO2)N1C.CC(=O)C1C2CCC(CS2)N1C.CC(=O)C1C2CCC(N2)N1C.CC(=O)C1C2CCC(NC2)N1C.CC(=O)C1C2CCC(O2)N1C.CC(=O)C1C2CCC(OC2)N1C.CC(=O)C1C2CCC(S2)N1C.CC(=O)C1C2CCC(SC2)N1C Chemical compound CC(=O)C1C2C=CC(C2)N1C.CC(=O)C1C2C=CC(CC2)N1C.CC(=O)C1C2C=CC(CN2)N1C.CC(=O)C1C2C=CC(CO2)N1C.CC(=O)C1C2C=CC(CS2)N1C.CC(=O)C1C2C=CC(N2)N1C.CC(=O)C1C2C=CC(NC2)N1C.CC(=O)C1C2C=CC(O2)N1C.CC(=O)C1C2C=CC(OC2)N1C.CC(=O)C1C2C=CC(S2)N1C.CC(=O)C1C2C=CC(SC2)N1C.CC(=O)C1C2CCC(C2)N1C.CC(=O)C1C2CCC(CC2)N1C.CC(=O)C1C2CCC(CN2)N1C.CC(=O)C1C2CCC(CO2)N1C.CC(=O)C1C2CCC(CS2)N1C.CC(=O)C1C2CCC(N2)N1C.CC(=O)C1C2CCC(NC2)N1C.CC(=O)C1C2CCC(O2)N1C.CC(=O)C1C2CCC(OC2)N1C.CC(=O)C1C2CCC(S2)N1C.CC(=O)C1C2CCC(SC2)N1C CGGZQWXCRCDELY-UHFFFAOYSA-N 0.000 description 1
- CKGKPOJQBUWATK-UHFFFAOYSA-N CC(=O)C1C2CC2CN1C.CC(=O)C1C2CCCC2CN1C.CC(=O)C1C2CCCCC2CN1C.CC(=O)C1C2CCCNC2CN1C.CC(=O)C1C2CCCOC2CN1C.CC(=O)C1C2CCCSC2CN1C.CC(=O)C1C2CCNC2CN1C.CC(=O)C1C2CCNCC2CN1C.CC(=O)C1C2CCOC2CN1C.CC(=O)C1C2CCOCC2CN1C.CC(=O)C1C2CCSC2CN1C.CC(=O)C1C2CCSCC2CN1C.CC(=O)C1C2CNCC2CN1C.CC(=O)C1C2COCC2CN1C.CC(=O)C1C2CSCC2CN1C.CC(=O)C1C2NC2CN1C.CC(=O)C1C2NCCC2CN1C.CC(=O)C1C2OC2CN1C.CC(=O)C1C2OCCC2CN1C.CC(=O)C1C2SC2CN1C.CC(=O)C1C2SCCC2CN1C Chemical compound CC(=O)C1C2CC2CN1C.CC(=O)C1C2CCCC2CN1C.CC(=O)C1C2CCCCC2CN1C.CC(=O)C1C2CCCNC2CN1C.CC(=O)C1C2CCCOC2CN1C.CC(=O)C1C2CCCSC2CN1C.CC(=O)C1C2CCNC2CN1C.CC(=O)C1C2CCNCC2CN1C.CC(=O)C1C2CCOC2CN1C.CC(=O)C1C2CCOCC2CN1C.CC(=O)C1C2CCSC2CN1C.CC(=O)C1C2CCSCC2CN1C.CC(=O)C1C2CNCC2CN1C.CC(=O)C1C2COCC2CN1C.CC(=O)C1C2CSCC2CN1C.CC(=O)C1C2NC2CN1C.CC(=O)C1C2NCCC2CN1C.CC(=O)C1C2OC2CN1C.CC(=O)C1C2OCCC2CN1C.CC(=O)C1C2SC2CN1C.CC(=O)C1C2SCCC2CN1C CKGKPOJQBUWATK-UHFFFAOYSA-N 0.000 description 1
- TZKWFQOKHCDLRY-BSPNICBASA-N CC(=O)C1CC(OCC2=C3C=CC=CC3=CC=C2)CN1C.CC(=O)C1CC(OCC2=CC3=C(C=CC=C3)C=C2)CN1C.CC(=O)C1CC(OCC2=CC=CC=C2)CN1C.CC(=O)C1C[C@@H](N2N=C(C3=CC=CC=C3)C(C3=CC=CC=C3)=N2)CN1C Chemical compound CC(=O)C1CC(OCC2=C3C=CC=CC3=CC=C2)CN1C.CC(=O)C1CC(OCC2=CC3=C(C=CC=C3)C=C2)CN1C.CC(=O)C1CC(OCC2=CC=CC=C2)CN1C.CC(=O)C1C[C@@H](N2N=C(C3=CC=CC=C3)C(C3=CC=CC=C3)=N2)CN1C TZKWFQOKHCDLRY-BSPNICBASA-N 0.000 description 1
- GYJRUQCXBIBLDL-UHFFFAOYSA-N CC(=O)C1CC2C3=C(C=CC=C3)CC2N1C.CC(=O)C1CC2C3=C(C=CC=C3)NC2N1C.CC(=O)C1CC2C3=C(C=CC=C3)OC2N1C.CC(=O)C1CC2C3=C(C=CC=C3)SC2N1C.CC(=O)C1CC2CC2N1C.CC(=O)C1CC2CCC2N1C.CC(=O)C1CC2CCCC2N1C.CC(=O)C1CC2CCCCC2N1C.CC(=O)C1CC2CCNCC2N1C.CC(=O)C1CC2CCOCC2N1C.CC(=O)C1CC2CCSCC2N1C.CC(=O)C1CC2CNCC2N1C.CC(=O)C1CC2CNCCC2N1C.CC(=O)C1CC2COCC2N1C.CC(=O)C1CC2COCCC2N1C.CC(=O)C1CC2CSCC2N1C.CC(=O)C1CC2CSCCC2N1C Chemical compound CC(=O)C1CC2C3=C(C=CC=C3)CC2N1C.CC(=O)C1CC2C3=C(C=CC=C3)NC2N1C.CC(=O)C1CC2C3=C(C=CC=C3)OC2N1C.CC(=O)C1CC2C3=C(C=CC=C3)SC2N1C.CC(=O)C1CC2CC2N1C.CC(=O)C1CC2CCC2N1C.CC(=O)C1CC2CCCC2N1C.CC(=O)C1CC2CCCCC2N1C.CC(=O)C1CC2CCNCC2N1C.CC(=O)C1CC2CCOCC2N1C.CC(=O)C1CC2CCSCC2N1C.CC(=O)C1CC2CNCC2N1C.CC(=O)C1CC2CNCCC2N1C.CC(=O)C1CC2COCC2N1C.CC(=O)C1CC2COCCC2N1C.CC(=O)C1CC2CSCC2N1C.CC(=O)C1CC2CSCCC2N1C GYJRUQCXBIBLDL-UHFFFAOYSA-N 0.000 description 1
- WYKUWMVWIMQFEZ-UHFFFAOYSA-N CC(=O)C1CC2C3=C(C=CC=N3)NC2N1C.CC(=O)C1CC2C3=C(C=CN=C3)NC2N1C.CC(=O)C1CC2C3=C(C=NC=C3)NC2N1C.CC(=O)C1CC2C3=C(N=CC=C3)NC2N1C.CC(=O)C1CC2C3CCCCC3CC2N1C.CC(=O)C1CC2C3CCCCC3NC2N1C.CC(=O)C1CC2C3CCCCC3OC2N1C.CC(=O)C1CC2C3CCCCC3SC2N1C.CC(=O)C1CC2C3CCCNC3NC2N1C.CC(=O)C1CC2C3CCNCC3NC2N1C.CC(=O)C1CC2C3CNCCC3NC2N1C.CC(=O)C1CC2C3NCCCC3NC2N1C Chemical compound CC(=O)C1CC2C3=C(C=CC=N3)NC2N1C.CC(=O)C1CC2C3=C(C=CN=C3)NC2N1C.CC(=O)C1CC2C3=C(C=NC=C3)NC2N1C.CC(=O)C1CC2C3=C(N=CC=C3)NC2N1C.CC(=O)C1CC2C3CCCCC3CC2N1C.CC(=O)C1CC2C3CCCCC3NC2N1C.CC(=O)C1CC2C3CCCCC3OC2N1C.CC(=O)C1CC2C3CCCCC3SC2N1C.CC(=O)C1CC2C3CCCNC3NC2N1C.CC(=O)C1CC2C3CCNCC3NC2N1C.CC(=O)C1CC2C3CNCCC3NC2N1C.CC(=O)C1CC2C3NCCCC3NC2N1C WYKUWMVWIMQFEZ-UHFFFAOYSA-N 0.000 description 1
- AKQFFYHULIZGAF-UHFFFAOYSA-N CC(=O)C1CCC2CC3(CCCN3C)C(=O)N21.CC(=O)C1CCCC2CC3(CCCN3C)C(=O)N21.CC(=O)C1CCNC2CC3(CCCN3C)C(=O)N21.CC(=O)C1CCOC2CC3(CCCN3C)C(=O)N21.CC(=O)C1CCSC2CC3(CCCN3C)C(=O)N21.CC(=O)C1CNC2CC3(CCCN3C)C(=O)N21.CC(=O)C1COC2CC3(CCCN3C)C(=O)N21.CC(=O)C1CSC2CC3(CCCN3C)C(=O)N21.CNC1CCC2CCC(C(C)=O)N2C1=O.CNC1CCCC2CCC(C(C)=O)N2C1=O.CNC1CCNC2CCC(C(C)=O)N2C1=O.CNC1CCOC2CCC(C(C)=O)N2C1=O.CNC1CCSC2CCC(C(C)=O)N2C1=O.CNC1CNC2CCC(C(C)=O)N2C1=O.CNC1COC2CCC(C(C)=O)N2C1=O.CNC1CSC2CCC(C(C)=O)N2C1=O Chemical compound CC(=O)C1CCC2CC3(CCCN3C)C(=O)N21.CC(=O)C1CCCC2CC3(CCCN3C)C(=O)N21.CC(=O)C1CCNC2CC3(CCCN3C)C(=O)N21.CC(=O)C1CCOC2CC3(CCCN3C)C(=O)N21.CC(=O)C1CCSC2CC3(CCCN3C)C(=O)N21.CC(=O)C1CNC2CC3(CCCN3C)C(=O)N21.CC(=O)C1COC2CC3(CCCN3C)C(=O)N21.CC(=O)C1CSC2CC3(CCCN3C)C(=O)N21.CNC1CCC2CCC(C(C)=O)N2C1=O.CNC1CCCC2CCC(C(C)=O)N2C1=O.CNC1CCNC2CCC(C(C)=O)N2C1=O.CNC1CCOC2CCC(C(C)=O)N2C1=O.CNC1CCSC2CCC(C(C)=O)N2C1=O.CNC1CNC2CCC(C(C)=O)N2C1=O.CNC1COC2CCC(C(C)=O)N2C1=O.CNC1CSC2CCC(C(C)=O)N2C1=O AKQFFYHULIZGAF-UHFFFAOYSA-N 0.000 description 1
- PNYDYLNKDBSLPT-UHFFFAOYSA-N CC(=O)C1CCCNC(=O)C1C.CC(=O)C1CCNC(=O)N1C.CC(=O)C1CNC(=O)N1C.CNC1=NC=C2CCC(C(C)=O)N2C1=O.CNC1=NC=C2CCCC(C(C)=O)N2C1=O.CNC1=NC=C2CCCC(C(C)=O)N2C1=O.CNC1=NC=C2CCCCC(C(C)=O)N2C1=O.CNC1=NN=C2CCC(C(C)=O)N2C1=O.CNC1=NN=C2CCCCC(C(C)=O)N2C1=O.CNC1C(=O)N2C(C(C)=O)=CCC12.CNC1C(=O)N2C(C(C)=O)=CCCC12.CNC1C(=O)N2C(C(C)=O)=CCOC12.CNC1C(=O)N2C(C(C)=O)=CCSC12.CNC1C(=O)N2C(C(C)=O)=CNC12.CNC1C(=O)N2C(C(C)=O)=COC12.CNC1C(=O)N2C(C(C)=O)=CSC12.CNC1C(=O)N2C(C(C)=O)CCNC12 Chemical compound CC(=O)C1CCCNC(=O)C1C.CC(=O)C1CCNC(=O)N1C.CC(=O)C1CNC(=O)N1C.CNC1=NC=C2CCC(C(C)=O)N2C1=O.CNC1=NC=C2CCCC(C(C)=O)N2C1=O.CNC1=NC=C2CCCC(C(C)=O)N2C1=O.CNC1=NC=C2CCCCC(C(C)=O)N2C1=O.CNC1=NN=C2CCC(C(C)=O)N2C1=O.CNC1=NN=C2CCCCC(C(C)=O)N2C1=O.CNC1C(=O)N2C(C(C)=O)=CCC12.CNC1C(=O)N2C(C(C)=O)=CCCC12.CNC1C(=O)N2C(C(C)=O)=CCOC12.CNC1C(=O)N2C(C(C)=O)=CCSC12.CNC1C(=O)N2C(C(C)=O)=CNC12.CNC1C(=O)N2C(C(C)=O)=COC12.CNC1C(=O)N2C(C(C)=O)=CSC12.CNC1C(=O)N2C(C(C)=O)CCNC12 PNYDYLNKDBSLPT-UHFFFAOYSA-N 0.000 description 1
- YIHGSCCMNQTEPU-UHFFFAOYSA-N CC(=O)C1COCC2CC(N)C(=O)N21.CNC1CC2CCC(C(C)=O)N2C1=O.CNC1CC2CCCC(C(C)=O)N2C1=O.CNC1CC2CNCC(C(C)=O)N2C1=O.CNC1CC2CSCC(C(C)=O)N2C1=O.CNC1CC2NCC(C(C)=O)N2C1=O.CNC1CC2NCCC(C(C)=O)N2C1=O.CNC1CC2OCC(C(C)=O)N2C1=O.CNC1CC2OCCC(C=O)N2C1=O.CNC1CC2SCC(C(C)=O)N2C1=O.CNC1CC2SCCC(C(C)=O)N2C1=O.CNC1CCC2CCC(C(C)=O)N2C1=O.CNC1CCC2CCCC(C(C)=O)N2C1=O.CNC1CCC2NCC(C(C)=O)N2C1=O.CNC1CCC2OCC(C(C)=O)N2C1=O.CNC1CCC2SCC(C(C)=O)N2C1=O Chemical compound CC(=O)C1COCC2CC(N)C(=O)N21.CNC1CC2CCC(C(C)=O)N2C1=O.CNC1CC2CCCC(C(C)=O)N2C1=O.CNC1CC2CNCC(C(C)=O)N2C1=O.CNC1CC2CSCC(C(C)=O)N2C1=O.CNC1CC2NCC(C(C)=O)N2C1=O.CNC1CC2NCCC(C(C)=O)N2C1=O.CNC1CC2OCC(C(C)=O)N2C1=O.CNC1CC2OCCC(C=O)N2C1=O.CNC1CC2SCC(C(C)=O)N2C1=O.CNC1CC2SCCC(C(C)=O)N2C1=O.CNC1CCC2CCC(C(C)=O)N2C1=O.CNC1CCC2CCCC(C(C)=O)N2C1=O.CNC1CCC2NCC(C(C)=O)N2C1=O.CNC1CCC2OCC(C(C)=O)N2C1=O.CNC1CCC2SCC(C(C)=O)N2C1=O YIHGSCCMNQTEPU-UHFFFAOYSA-N 0.000 description 1
- VBFHBNDIYRINFA-FCDSUDIZSA-N CC(=O)O.CC(C)(C)OC(=O)[C@@H]1C[C@@H](OC2=CC=C(Cl)C=N2)CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=CN=CC=N1)C1CCCCC1)C(C)(C)C.CC(C)(C)OC(=O)[C@@H]1C[C@H](O)CN1C(=O)OCC1=CC=CC=C1.CC(C)(C)OC(=O)[C@@H]1C[C@H](O)CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=CN=CC=N1)C1CCCCC1)C(C)(C)C.CC(Cl)Cl.CCO.CCO.CN[C@H](C(=O)N1C[C@@H](O)C[C@H]1C(=O)OC(C)(C)C)C(C)(C)C.CN[C@H](C(=O)N[C@H](C(=O)N1C[C@@H](O)C[C@H]1C(=O)OC(C)(C)C)C(C)(C)C)C1CCCCC1.OC1=CC=C(Cl)C=N1 Chemical compound CC(=O)O.CC(C)(C)OC(=O)[C@@H]1C[C@@H](OC2=CC=C(Cl)C=N2)CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=CN=CC=N1)C1CCCCC1)C(C)(C)C.CC(C)(C)OC(=O)[C@@H]1C[C@H](O)CN1C(=O)OCC1=CC=CC=C1.CC(C)(C)OC(=O)[C@@H]1C[C@H](O)CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=CN=CC=N1)C1CCCCC1)C(C)(C)C.CC(Cl)Cl.CCO.CCO.CN[C@H](C(=O)N1C[C@@H](O)C[C@H]1C(=O)OC(C)(C)C)C(C)(C)C.CN[C@H](C(=O)N[C@H](C(=O)N1C[C@@H](O)C[C@H]1C(=O)OC(C)(C)C)C(C)(C)C)C1CCCCC1.OC1=CC=C(Cl)C=N1 VBFHBNDIYRINFA-FCDSUDIZSA-N 0.000 description 1
- VDXUKJVKBSMANH-UHFFFAOYSA-N CC(C(CC(CCC1)C2C1CCC1NC)N2C1=O)=O Chemical compound CC(C(CC(CCC1)C2C1CCC1NC)N2C1=O)=O VDXUKJVKBSMANH-UHFFFAOYSA-N 0.000 description 1
- NSMOXIVZXWMBSW-UHFFFAOYSA-N CC(C(CNCC1CCCC2NC)N1C2=O)=O Chemical compound CC(C(CNCC1CCCC2NC)N1C2=O)=O NSMOXIVZXWMBSW-UHFFFAOYSA-N 0.000 description 1
- RAOMONHYIAPFHN-UHFFFAOYSA-N CC(C(Cc1c2c(CCC3NC)ccc1)N2C3=O)=O Chemical compound CC(C(Cc1c2c(CCC3NC)ccc1)N2C3=O)=O RAOMONHYIAPFHN-UHFFFAOYSA-N 0.000 description 1
- MAYNPPZFBXTFIN-ZBCLICGJSA-N CC(C)(C)C(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2N1C(C)(C)C.CC(C)(C)C(=O)[C@@H]1C[C@@H]2CCC[C@@H]2N1C(C)(C)C Chemical compound CC(C)(C)C(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2N1C(C)(C)C.CC(C)(C)C(=O)[C@@H]1C[C@@H]2CCC[C@@H]2N1C(C)(C)C MAYNPPZFBXTFIN-ZBCLICGJSA-N 0.000 description 1
- YNQZVOWNJKASKQ-UHFFFAOYSA-N CC(C)(C)C1=NC=CN=C1 Chemical compound CC(C)(C)C1=NC=CN=C1 YNQZVOWNJKASKQ-UHFFFAOYSA-N 0.000 description 1
- CSLZVCDTYBHCEL-FXOXKUTDSA-N CC(C)(C)C1C(=O)CC(=O)C1C(C)(C)C.CC(C)(C)C1C2CCC(C2)C1C(C)(C)C.CC(C)(C)C1C2CCC(C2)C1C(C)(C)C.CC(C)(C)C1C2CCC(O2)C1C(C)(C)C.CC(C)(C)C1C=CC(=O)CC1C(C)(C)C.CC(C)(C)C1CCC(=O)CC1C(C)(C)C.CC(C)(C)[C@@H]1COC2CCCCC2[C@@H]1C(C)(C)C.CC(C)(C)[C@H]1C2=C(C=CC=C2)OC[C@H]1C(C)(C)C.CC(C)(C)[C@H]1CS(=O)(=O)C[C@H]1C(C)(C)C Chemical compound CC(C)(C)C1C(=O)CC(=O)C1C(C)(C)C.CC(C)(C)C1C2CCC(C2)C1C(C)(C)C.CC(C)(C)C1C2CCC(C2)C1C(C)(C)C.CC(C)(C)C1C2CCC(O2)C1C(C)(C)C.CC(C)(C)C1C=CC(=O)CC1C(C)(C)C.CC(C)(C)C1CCC(=O)CC1C(C)(C)C.CC(C)(C)[C@@H]1COC2CCCCC2[C@@H]1C(C)(C)C.CC(C)(C)[C@H]1C2=C(C=CC=C2)OC[C@H]1C(C)(C)C.CC(C)(C)[C@H]1CS(=O)(=O)C[C@H]1C(C)(C)C CSLZVCDTYBHCEL-FXOXKUTDSA-N 0.000 description 1
- GFGWVHAOSDMSBS-UHFFFAOYSA-N CC(C)(C)C1C(C2=CC=CC=C2)C2C3=C(C=CC=C3)NC2N1C(C)(C)C.CC(C)(C)C1C(C2=CC=CC=C2)C2C3=C(N=CC=C3)NC2N1C(C)(C)C.CC(C)(C)C1C(C2CCCCC2)C2C3CCCCC3NC2N1C(C)(C)C.CC(C)(C)C1C2C3=C(C=CC=C3)NC2N(C(C)(C)C)C1C(C)(C)C.CC(C)(C)C1C2C3=C(C=NC=C3)NC2N(C(C)(C)C)C1C(C)(C)C.CC(C)(C)C1C2C3=C(N=CC=C3)NC2N(C(C)(C)C)C1C(C)(C)C.CC(C)(C)C1C2C3CCCCC3NC2N(C(C)(C)C)C1C(C)(C)C.CC(C)C1C2C3=C(C=CC=C3)NC2N(C(C)(C)C)C1C(C)(C)C.CC(C)C1C2C3=C(C=NC=C3)NC2N(C(C)(C)C)C1C(C)(C)C.CC(C)C1C2C3=C(N=CC=C3)NC2N(C(C)(C)C)C1C(C)(C)C.CC(C)C1C2C3CCCCC3NC2N(C(C)(C)C)C1C(C)(C)C.CC(C)C1C2C3CCCNC3NC2N(C(C)(C)C)C1C(C)(C)C Chemical compound CC(C)(C)C1C(C2=CC=CC=C2)C2C3=C(C=CC=C3)NC2N1C(C)(C)C.CC(C)(C)C1C(C2=CC=CC=C2)C2C3=C(N=CC=C3)NC2N1C(C)(C)C.CC(C)(C)C1C(C2CCCCC2)C2C3CCCCC3NC2N1C(C)(C)C.CC(C)(C)C1C2C3=C(C=CC=C3)NC2N(C(C)(C)C)C1C(C)(C)C.CC(C)(C)C1C2C3=C(C=NC=C3)NC2N(C(C)(C)C)C1C(C)(C)C.CC(C)(C)C1C2C3=C(N=CC=C3)NC2N(C(C)(C)C)C1C(C)(C)C.CC(C)(C)C1C2C3CCCCC3NC2N(C(C)(C)C)C1C(C)(C)C.CC(C)C1C2C3=C(C=CC=C3)NC2N(C(C)(C)C)C1C(C)(C)C.CC(C)C1C2C3=C(C=NC=C3)NC2N(C(C)(C)C)C1C(C)(C)C.CC(C)C1C2C3=C(N=CC=C3)NC2N(C(C)(C)C)C1C(C)(C)C.CC(C)C1C2C3CCCCC3NC2N(C(C)(C)C)C1C(C)(C)C.CC(C)C1C2C3CCCNC3NC2N(C(C)(C)C)C1C(C)(C)C GFGWVHAOSDMSBS-UHFFFAOYSA-N 0.000 description 1
- XICPXESGGFBCGO-UHFFFAOYSA-N CC(C)(C)C1C(C2=CC=CC=C2)C2C3=C(C=CC=N3)NC2N1C(C)(C)C.CC(C)(C)C1C(C2=CC=CC=C2)C2C3=C(C=CN=C3)NC2N1C(C)(C)C.CC(C)(C)C1C2C3=C(C=CC=N3)NC2N(C(C)(C)C)C1C(C)(C)C.CC(C)C1C2C3=C(C=CC=N3)NC2N(C(C)(C)C)C1C(C)(C)C.CC(C)C1C2C3CNCCC3NC2N(C(C)(C)C)C1C(C)(C)C.CC(C)C1C2C3NCCCC3NC2N(C(C)(C)C)C1C(C)(C)C Chemical compound CC(C)(C)C1C(C2=CC=CC=C2)C2C3=C(C=CC=N3)NC2N1C(C)(C)C.CC(C)(C)C1C(C2=CC=CC=C2)C2C3=C(C=CN=C3)NC2N1C(C)(C)C.CC(C)(C)C1C2C3=C(C=CC=N3)NC2N(C(C)(C)C)C1C(C)(C)C.CC(C)C1C2C3=C(C=CC=N3)NC2N(C(C)(C)C)C1C(C)(C)C.CC(C)C1C2C3CNCCC3NC2N(C(C)(C)C)C1C(C)(C)C.CC(C)C1C2C3NCCCC3NC2N(C(C)(C)C)C1C(C)(C)C XICPXESGGFBCGO-UHFFFAOYSA-N 0.000 description 1
- YGAQHODZEIKSSG-UHFFFAOYSA-N CC(C)(C)C1C(C2=CC=CC=C2)C2C3=C(C=NC=C3)NC2N1C(C)(C)C.CC(C)(C)C1C(C2CCCCC2)C2C3CCCNC3NC2N1C(C)(C)C.CC(C)(C)C1C(C2CCCCC2)C2C3CCNCC3NC2N1C(C)(C)C.CC(C)(C)C1C(C2CCCCC2)C2C3CNCCC3NC2N1C(C)(C)C.CC(C)(C)C1C(C2CCCCC2)C2C3NCCCC3NC2N1C(C)(C)C.CC(C)(C)C1C2C3=C(C=CN=C3)NC2N(C(C)(C)C)C1C(C)(C)C.CC(C)(C)C1C2C3CCCNC3NC2N(C(C)(C)C)C1C(C)(C)C.CC(C)(C)C1C2C3CCNCC3NC2N(C(C)(C)C)C1C(C)(C)C.CC(C)(C)C1C2C3CNCCC3NC2N(C(C)(C)C)C1C(C)(C)C.CC(C)(C)C1C2C3NCCCC3NC2N(C(C)(C)C)C1C(C)(C)C.CC(C)C1C2C3=C(C=CN=C3)NC2N(C(C)(C)C)C1C(C)(C)C.CC(C)C1C2C3CCNCC3NC2N(C(C)(C)C)C1C(C)(C)C Chemical compound CC(C)(C)C1C(C2=CC=CC=C2)C2C3=C(C=NC=C3)NC2N1C(C)(C)C.CC(C)(C)C1C(C2CCCCC2)C2C3CCCNC3NC2N1C(C)(C)C.CC(C)(C)C1C(C2CCCCC2)C2C3CCNCC3NC2N1C(C)(C)C.CC(C)(C)C1C(C2CCCCC2)C2C3CNCCC3NC2N1C(C)(C)C.CC(C)(C)C1C(C2CCCCC2)C2C3NCCCC3NC2N1C(C)(C)C.CC(C)(C)C1C2C3=C(C=CN=C3)NC2N(C(C)(C)C)C1C(C)(C)C.CC(C)(C)C1C2C3CCCNC3NC2N(C(C)(C)C)C1C(C)(C)C.CC(C)(C)C1C2C3CCNCC3NC2N(C(C)(C)C)C1C(C)(C)C.CC(C)(C)C1C2C3CNCCC3NC2N(C(C)(C)C)C1C(C)(C)C.CC(C)(C)C1C2C3NCCCC3NC2N(C(C)(C)C)C1C(C)(C)C.CC(C)C1C2C3=C(C=CN=C3)NC2N(C(C)(C)C)C1C(C)(C)C.CC(C)C1C2C3CCNCC3NC2N(C(C)(C)C)C1C(C)(C)C YGAQHODZEIKSSG-UHFFFAOYSA-N 0.000 description 1
- LKFJPNILNWWEIP-UHFFFAOYSA-N CC(C)(C)C1C2C(C3=CC=CC=C3)=NOC23CC3N1C(C)(C)C.CC(C)(C)C1C2C(C3=CC=CC=C3)=NOC23CCCC3N1C(C)(C)C.CC(C)(C)C1C2C3CCC(C3)C23CC3N1C(C)(C)C.CC(C)(C)C1C2C3CCC(C3)C23CCCC3N1C(C)(C)C.CC(C)(C)C1C2C3CCC(C3)C23CCCCC3N1C(C)(C)C.CC(C)(C)C1C2C3CCC(O3)C23CCCC3N1C(C)(C)C.CC(C)(C)C1C2CCCCC23CC3N1C(C)(C)C.CC(C)(C)C1C2CCCCC23CCCC3N1C(C)(C)C.CC(C)(C)C1C2N=NCC23CC3N1C(C)(C)C.CC(C)(C)C1C2N=NCC23CCCC3N1C(C)(C)C.CC1CC(C)C23CCCC2N(C(C)(C)C)C(C(C)(C)C)C13.CN1OC23CC2N(C(C)(C)C)C(C(C)(C)C)C3C1C1=CC=CC=C1.CN1OC23CCCC2N(C(C)(C)C)C(C(C)(C)C)C3C1C1=CC=CC=C1 Chemical compound CC(C)(C)C1C2C(C3=CC=CC=C3)=NOC23CC3N1C(C)(C)C.CC(C)(C)C1C2C(C3=CC=CC=C3)=NOC23CCCC3N1C(C)(C)C.CC(C)(C)C1C2C3CCC(C3)C23CC3N1C(C)(C)C.CC(C)(C)C1C2C3CCC(C3)C23CCCC3N1C(C)(C)C.CC(C)(C)C1C2C3CCC(C3)C23CCCCC3N1C(C)(C)C.CC(C)(C)C1C2C3CCC(O3)C23CCCC3N1C(C)(C)C.CC(C)(C)C1C2CCCCC23CC3N1C(C)(C)C.CC(C)(C)C1C2CCCCC23CCCC3N1C(C)(C)C.CC(C)(C)C1C2N=NCC23CC3N1C(C)(C)C.CC(C)(C)C1C2N=NCC23CCCC3N1C(C)(C)C.CC1CC(C)C23CCCC2N(C(C)(C)C)C(C(C)(C)C)C13.CN1OC23CC2N(C(C)(C)C)C(C(C)(C)C)C3C1C1=CC=CC=C1.CN1OC23CCCC2N(C(C)(C)C)C(C(C)(C)C)C3C1C1=CC=CC=C1 LKFJPNILNWWEIP-UHFFFAOYSA-N 0.000 description 1
- ZWQNKRITIPUCHG-UHFFFAOYSA-N CC(C)(C)C1CC(OC2=CC=CC3=C2C=CN=C3)CN1C(C)(C)C.CC(C)(C)C1CC(OC2=CC=NC3=C2C=CC(C(F)(F)F)=C3)CN1C(C)(C)C.CC(C)(C)C1CC(OC2=CC=NC3=C2C=CC(Cl)=C3)CN1C(C)(C)C.CC(C)(C)C1CC(OC2=CC=NC3=C2C=CC=C3)CN1C(C)(C)C.CC(C)(C)C1CC(OC2=CN=CC3=C2C=CC=C3)CN1C(C)(C)C.CC(C)(C)C1CC(OC2=NC=CC3=C2C=CC=C3)CN1C(C)(C)C.COC1=CC2=C(C=C1)C(OC1CC(C(C)(C)C)N(C(C)(C)C)C1)=CC(N)=N2.COC1=CC2=C(C=C1)C(OC1CC(C(C)(C)C)N(C(C)(C)C)C1)=CC=N2 Chemical compound CC(C)(C)C1CC(OC2=CC=CC3=C2C=CN=C3)CN1C(C)(C)C.CC(C)(C)C1CC(OC2=CC=NC3=C2C=CC(C(F)(F)F)=C3)CN1C(C)(C)C.CC(C)(C)C1CC(OC2=CC=NC3=C2C=CC(Cl)=C3)CN1C(C)(C)C.CC(C)(C)C1CC(OC2=CC=NC3=C2C=CC=C3)CN1C(C)(C)C.CC(C)(C)C1CC(OC2=CN=CC3=C2C=CC=C3)CN1C(C)(C)C.CC(C)(C)C1CC(OC2=NC=CC3=C2C=CC=C3)CN1C(C)(C)C.COC1=CC2=C(C=C1)C(OC1CC(C(C)(C)C)N(C(C)(C)C)C1)=CC(N)=N2.COC1=CC2=C(C=C1)C(OC1CC(C(C)(C)C)N(C(C)(C)C)C1)=CC=N2 ZWQNKRITIPUCHG-UHFFFAOYSA-N 0.000 description 1
- LLEBJOPPRYNBKL-UHFFFAOYSA-N CC(C)(C)C1CC(OC2=CC=CC=N2)CN1C(C)(C)C.CC(C)(C)C1CC(OC2=CC=NC=N2)CN1C(C)(C)C.CC(C)(C)C1CC(OC2=CC=NC=N2)CN1C(C)(C)C Chemical compound CC(C)(C)C1CC(OC2=CC=CC=N2)CN1C(C)(C)C.CC(C)(C)C1CC(OC2=CC=NC=N2)CN1C(C)(C)C.CC(C)(C)C1CC(OC2=CC=NC=N2)CN1C(C)(C)C LLEBJOPPRYNBKL-UHFFFAOYSA-N 0.000 description 1
- CFSADPQRDUAIOE-UHFFFAOYSA-N CC(C)(C)C1CC2=C(C=CC=C2)C1C(C)(C)C.CC(C)(C)C1CC2=C(C=CC=C2)C1C(C)(C)C.CC(C)(C)C1CC2=C(C=CC=N2)C1C(C)(C)C.CC(C)(C)C1CC2=C(C=CC=N2)C1C(C)(C)C.CC(C)(C)C1CC2=C(C=CN=C2)C1C(C)(C)C.CC(C)(C)C1CC2=C(C=NC=C2)C1C(C)(C)C.CC(C)(C)C1CC2=C(N=CC=C2)C1C(C)(C)C.CC(C)(C)C1CC2CCCC2C1C(C)(C)C.CC(C)(C)C1CC2CCCC2C1C(C)(C)C.CC(C)(C)C1CC2CCCCC2C1C(C)(C)C.CC(C)(C)C1CCCC1C(C)(C)C.CC(C)(C)C1CCOC1C(C)(C)C.CC(C)(C)C1CCSC1C(C)(C)C.CC(C)(C)C1OC2=C(C=CC=C2)C1C(C)(C)C.CC(C)(C)C1OC2=C(C=CC=N2)C1C(C)(C)C.CC(C)(C)C1OC2CCCC2C1C(C)(C)C.CC(C)(C)C1OC2CCCCC2C1C(C)(C)C.CC(C)(C)C1SC2=C(C=CC=C2)C1C(C)(C)C.CC(C)(C)C1SC2=C(C=CC=N2)C1C(C)(C)C.CC(C)(C)C1SC2CCCC2C1C(C)(C)C.CC(C)(C)C1SC2CCCCC2C1C(C)(C)C Chemical compound CC(C)(C)C1CC2=C(C=CC=C2)C1C(C)(C)C.CC(C)(C)C1CC2=C(C=CC=C2)C1C(C)(C)C.CC(C)(C)C1CC2=C(C=CC=N2)C1C(C)(C)C.CC(C)(C)C1CC2=C(C=CC=N2)C1C(C)(C)C.CC(C)(C)C1CC2=C(C=CN=C2)C1C(C)(C)C.CC(C)(C)C1CC2=C(C=NC=C2)C1C(C)(C)C.CC(C)(C)C1CC2=C(N=CC=C2)C1C(C)(C)C.CC(C)(C)C1CC2CCCC2C1C(C)(C)C.CC(C)(C)C1CC2CCCC2C1C(C)(C)C.CC(C)(C)C1CC2CCCCC2C1C(C)(C)C.CC(C)(C)C1CCCC1C(C)(C)C.CC(C)(C)C1CCOC1C(C)(C)C.CC(C)(C)C1CCSC1C(C)(C)C.CC(C)(C)C1OC2=C(C=CC=C2)C1C(C)(C)C.CC(C)(C)C1OC2=C(C=CC=N2)C1C(C)(C)C.CC(C)(C)C1OC2CCCC2C1C(C)(C)C.CC(C)(C)C1OC2CCCCC2C1C(C)(C)C.CC(C)(C)C1SC2=C(C=CC=C2)C1C(C)(C)C.CC(C)(C)C1SC2=C(C=CC=N2)C1C(C)(C)C.CC(C)(C)C1SC2CCCC2C1C(C)(C)C.CC(C)(C)C1SC2CCCCC2C1C(C)(C)C CFSADPQRDUAIOE-UHFFFAOYSA-N 0.000 description 1
- CIWDYFCQWARNBK-UHFFFAOYSA-N CC(C)(C)C1CC2=C(C=CC=C2)C1C(C)(C)C.CC(C)(C)C1CC2=C(C=CC=N2)C1C(C)(C)C.CC(C)(C)C1CC2=C(C=CN=C2)C1C(C)(C)C.CC(C)(C)C1CC2=C(C=NC=C2)C1C(C)(C)C.CC(C)(C)C1CC2=C(N=CC=C2)C1C(C)(C)C.CC(C)(C)C1CC2CCCC2C1C(C)(C)C.CC(C)(C)C1CC2CCCC2C1C(C)(C)C.CC(C)(C)C1CC2CCCCC2C1C(C)(C)C.CC(C)(C)C1CC2CCCCC2C1C(C)(C)C.CC(C)(C)C1CCCCC1C(C)(C)C.CC(C)(C)C1CCCOC1C(C)(C)C.CC(C)(C)C1CCCSC1C(C)(C)C.CC(C)(C)C1OC2CCCC2C1C(C)(C)C.CC(C)(C)C1OC2CCCCC2C1C(C)(C)C.CC(C)(C)C1OCCOC1C(C)(C)C.CC(C)(C)C1SC2CCCC2C1C(C)(C)C.CC(C)(C)C1SC2CCCCC2C1C(C)(C)C.CC(C)(C)C1SCCSC1C(C)(C)C.CC(C)(C)C1SCCSC1C(C)(C)C Chemical compound CC(C)(C)C1CC2=C(C=CC=C2)C1C(C)(C)C.CC(C)(C)C1CC2=C(C=CC=N2)C1C(C)(C)C.CC(C)(C)C1CC2=C(C=CN=C2)C1C(C)(C)C.CC(C)(C)C1CC2=C(C=NC=C2)C1C(C)(C)C.CC(C)(C)C1CC2=C(N=CC=C2)C1C(C)(C)C.CC(C)(C)C1CC2CCCC2C1C(C)(C)C.CC(C)(C)C1CC2CCCC2C1C(C)(C)C.CC(C)(C)C1CC2CCCCC2C1C(C)(C)C.CC(C)(C)C1CC2CCCCC2C1C(C)(C)C.CC(C)(C)C1CCCCC1C(C)(C)C.CC(C)(C)C1CCCOC1C(C)(C)C.CC(C)(C)C1CCCSC1C(C)(C)C.CC(C)(C)C1OC2CCCC2C1C(C)(C)C.CC(C)(C)C1OC2CCCCC2C1C(C)(C)C.CC(C)(C)C1OCCOC1C(C)(C)C.CC(C)(C)C1SC2CCCC2C1C(C)(C)C.CC(C)(C)C1SC2CCCCC2C1C(C)(C)C.CC(C)(C)C1SCCSC1C(C)(C)C.CC(C)(C)C1SCCSC1C(C)(C)C CIWDYFCQWARNBK-UHFFFAOYSA-N 0.000 description 1
- DQIBTFNTMRTAGW-UHFFFAOYSA-N CC(C)(C)C1CC2=CC=CC=C2N1C(C)(C)C.CC(C)(C)C1CC2CCCC2N1C(C)(C)C.CC(C)(C)C1CC2CCCCC2N1C(C)(C)C Chemical compound CC(C)(C)C1CC2=CC=CC=C2N1C(C)(C)C.CC(C)(C)C1CC2CCCC2N1C(C)(C)C.CC(C)(C)C1CC2CCCCC2N1C(C)(C)C DQIBTFNTMRTAGW-UHFFFAOYSA-N 0.000 description 1
- BBUNLYSLUKUHBP-UHFFFAOYSA-N CC(C)(C)CC(F)(F)F.CC(C)(C)CC(F)F.CC(C)(C)CS.CCC(C)(C)C.CCCC(C)(C)C Chemical compound CC(C)(C)CC(F)(F)F.CC(C)(C)CC(F)F.CC(C)(C)CS.CCC(C)(C)C.CCCC(C)(C)C BBUNLYSLUKUHBP-UHFFFAOYSA-N 0.000 description 1
- PEIKIFBMIUKOOV-SHKDCZALSA-N CC(C)(C)[C@@H]1CC(F)(F)CN1C(C)(C)C.CC(C)(C)[C@@H]1CC2(CC3=C(C=CC=C3)C2)CN1C(C)(C)C.C[C@@H]1CC2(CN1C)SCCCS2 Chemical compound CC(C)(C)[C@@H]1CC(F)(F)CN1C(C)(C)C.CC(C)(C)[C@@H]1CC2(CC3=C(C=CC=C3)C2)CN1C(C)(C)C.C[C@@H]1CC2(CN1C)SCCCS2 PEIKIFBMIUKOOV-SHKDCZALSA-N 0.000 description 1
- UORLBZTXWUGNLD-UZEMROAUSA-N CC(C)(C)[C@H](NC(=O)[C@@H](NC(=O)C1=CN=CC=N1)C1CCCCC1)C(=O)N1CC2(C[C@H]1C(=O)O)SCCCS2.CCC[C@H](N)C(=O)NS(=O)(=O)C1=CC=CC=C1.CCC[C@H](NC(=O)[C@@H]1CC2(CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=CN=CC=N1)C1CCCCC1)C(C)(C)C)SCCCS2)C(=O)NS(=O)(=O)C1=CC=CC=C1 Chemical compound CC(C)(C)[C@H](NC(=O)[C@@H](NC(=O)C1=CN=CC=N1)C1CCCCC1)C(=O)N1CC2(C[C@H]1C(=O)O)SCCCS2.CCC[C@H](N)C(=O)NS(=O)(=O)C1=CC=CC=C1.CCC[C@H](NC(=O)[C@@H]1CC2(CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=CN=CC=N1)C1CCCCC1)C(C)(C)C)SCCCS2)C(=O)NS(=O)(=O)C1=CC=CC=C1 UORLBZTXWUGNLD-UZEMROAUSA-N 0.000 description 1
- YUFNEWYOKMLUSL-IPKUIPPZSA-N CC(C)(C)[C@H](NC(=O)[C@@H](NC(=O)C1=CN=CC=N1)C1CCCCC1)C(=O)N1C[C@H](OC2=CC=C(Cl)C=N2)C[C@H]1C(=O)O.CCC[C@H](N)C(=O)NS(=O)(=O)C1=CC=CC=C1.CCC[C@H](NC(=O)[C@@H]1C[C@@H](OC2=CC=C(Cl)C=N2)CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=CN=CC=N1)C1CCCCC1)C(C)(C)C)C(=O)NS(=O)(=O)C1=CC=CC=C1 Chemical compound CC(C)(C)[C@H](NC(=O)[C@@H](NC(=O)C1=CN=CC=N1)C1CCCCC1)C(=O)N1C[C@H](OC2=CC=C(Cl)C=N2)C[C@H]1C(=O)O.CCC[C@H](N)C(=O)NS(=O)(=O)C1=CC=CC=C1.CCC[C@H](NC(=O)[C@@H]1C[C@@H](OC2=CC=C(Cl)C=N2)CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=CN=CC=N1)C1CCCCC1)C(C)(C)C)C(=O)NS(=O)(=O)C1=CC=CC=C1 YUFNEWYOKMLUSL-IPKUIPPZSA-N 0.000 description 1
- IDNMEPZXFBVBIY-UHFFFAOYSA-N CC(NS(C)(=O)=O)C(C)(C)C.COC(=O)NC(C(C)C)C(C)(C)C.COC(=O)NC(C)C(C)(C)C.COC(=O)NCC(NC(=O)OC)C(C)(C)C Chemical compound CC(NS(C)(=O)=O)C(C)(C)C.COC(=O)NC(C(C)C)C(C)(C)C.COC(=O)NC(C)C(C)(C)C.COC(=O)NCC(NC(=O)OC)C(C)(C)C IDNMEPZXFBVBIY-UHFFFAOYSA-N 0.000 description 1
- NEHMUNBIQMRODL-GINSOKNKSA-N CCCC(NC(=O)C1[C@H]2CCCC2CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=CN=CC=N1)C(C)C)C(C)C)C(=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O Chemical compound CCCC(NC(=O)C1[C@H]2CCCC2CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=CN=CC=N1)C(C)C)C(C)C)C(=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O NEHMUNBIQMRODL-GINSOKNKSA-N 0.000 description 1
- AYDOHBHZRGXAHG-AFMHHQJYSA-N CCC[C@H](C)C(=O)NS(=O)(=O)C1=CC=CC=C1.CCC[C@H](C)C(=O)NS(=O)(=O)C1=CC=CC=C1.CCC[C@H](C)C(=O)NS(=O)(=O)C1=CC=CC=C1.CNC(=O)[C@@H]1CC2(CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=C(C(C)=O)C(C)=C(C)N1)C1CCCCC1)C(C)(C)C)SCCCS2.CNC(=O)[C@@H]1CC2(CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=CN=CC=N1)C1CCCCC1)C(C)(C)C)SCCCS2.CNC(=O)[C@@H]1C[C@@H](OC2=CC=C(Cl)C=N2)CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=CN=CC=N1)C1CCCCC1)C(C)(C)C Chemical compound CCC[C@H](C)C(=O)NS(=O)(=O)C1=CC=CC=C1.CCC[C@H](C)C(=O)NS(=O)(=O)C1=CC=CC=C1.CCC[C@H](C)C(=O)NS(=O)(=O)C1=CC=CC=C1.CNC(=O)[C@@H]1CC2(CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=C(C(C)=O)C(C)=C(C)N1)C1CCCCC1)C(C)(C)C)SCCCS2.CNC(=O)[C@@H]1CC2(CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=CN=CC=N1)C1CCCCC1)C(C)(C)C)SCCCS2.CNC(=O)[C@@H]1C[C@@H](OC2=CC=C(Cl)C=N2)CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=CN=CC=N1)C1CCCCC1)C(C)(C)C AYDOHBHZRGXAHG-AFMHHQJYSA-N 0.000 description 1
- KCPNXRSXLKDVPR-JKUBKGJBSA-N CCC[C@H](N)C(=O)NS(=O)(=O)C1=CC=CC=C1.CCC[C@H](N)C(=O)NS(=O)(=O)C1=CC=CC=C1.CCC[C@H](NC(=O)OC(C)(C)C)C(=O)NS(=O)(=O)C1=CC=CC=C1.CCC[C@H](NC(=O)OC(C)(C)C)C(=O)O.Cl.NS(=O)(=O)C1=CC=CC=C1.[2H]B[U] Chemical compound CCC[C@H](N)C(=O)NS(=O)(=O)C1=CC=CC=C1.CCC[C@H](N)C(=O)NS(=O)(=O)C1=CC=CC=C1.CCC[C@H](NC(=O)OC(C)(C)C)C(=O)NS(=O)(=O)C1=CC=CC=C1.CCC[C@H](NC(=O)OC(C)(C)C)C(=O)O.Cl.NS(=O)(=O)C1=CC=CC=C1.[2H]B[U] KCPNXRSXLKDVPR-JKUBKGJBSA-N 0.000 description 1
- SWYYCWBRBOEZDM-DWIHFJQFSA-N CCC[C@H](N)C(=O)NS(=O)C1=CC=CC=C1.CCC[C@H](N)C(=O)NS(=O)C1=CC=CC=C1.CCC[C@H](NC(=O)OC(C)(C)C)C(=O)NS(=O)C1=CC=CC=C1.CCC[C@H](NC(=O)OC(C)(C)C)C(=O)O.Cl.NS(=O)C1=CC=CC=C1.O=C(N(C1=CC=CC=C1)C1=CC=CC=C1)[N+]1=CC=CC=C1 Chemical compound CCC[C@H](N)C(=O)NS(=O)C1=CC=CC=C1.CCC[C@H](N)C(=O)NS(=O)C1=CC=CC=C1.CCC[C@H](NC(=O)OC(C)(C)C)C(=O)NS(=O)C1=CC=CC=C1.CCC[C@H](NC(=O)OC(C)(C)C)C(=O)O.Cl.NS(=O)C1=CC=CC=C1.O=C(N(C1=CC=CC=C1)C1=CC=CC=C1)[N+]1=CC=CC=C1 SWYYCWBRBOEZDM-DWIHFJQFSA-N 0.000 description 1
- GTAFOUHZJYBVCK-PTCKCEFPSA-N CCC[C@H](NC(=O)[C@@H]1CC2(CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=C(C(C)=O)C(C)=C(C)N1)C1CCCCC1)C(C)(C)C)SCCCS2)C(=O)NS(=O)(=O)C1=CC=CC=C1.CCC[C@H](NC(=O)[C@@H]1CC2(CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=CN=CC=N1)C1CCCCC1)C(C)(C)C)SCCCS2)C(=O)NS(=O)(=O)C1=CC=CC=C1.CCC[C@H](NC(=O)[C@@H]1C[C@@H](OC2=CC=C(Cl)C=N2)CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=CN=CC=N1)C1CCCCC1)C(C)(C)C)C(=O)NS(=O)(=O)C1=CC=CC=C1 Chemical compound CCC[C@H](NC(=O)[C@@H]1CC2(CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=C(C(C)=O)C(C)=C(C)N1)C1CCCCC1)C(C)(C)C)SCCCS2)C(=O)NS(=O)(=O)C1=CC=CC=C1.CCC[C@H](NC(=O)[C@@H]1CC2(CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=CN=CC=N1)C1CCCCC1)C(C)(C)C)SCCCS2)C(=O)NS(=O)(=O)C1=CC=CC=C1.CCC[C@H](NC(=O)[C@@H]1C[C@@H](OC2=CC=C(Cl)C=N2)CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=CN=CC=N1)C1CCCCC1)C(C)(C)C)C(=O)NS(=O)(=O)C1=CC=CC=C1 GTAFOUHZJYBVCK-PTCKCEFPSA-N 0.000 description 1
- ITRCGRGACDBFSX-WBLBOCGKSA-N CCOC(=O)C=O.CCOC(=O)[C@@H]1[C@H]2C=C[C@H](C2)N1[C@H](C)C1=CC=CC=C1.CCOC(=O)[C@H]1N[C@@H]2CC[C@H]1C2.C[C@@H](N)C1=CC=CC=C1.C[Pd].O=C(O)[C@@H]1[C@H]2CC[C@H](C2)N1C(=O)OCC1=CC=CC=C1 Chemical compound CCOC(=O)C=O.CCOC(=O)[C@@H]1[C@H]2C=C[C@H](C2)N1[C@H](C)C1=CC=CC=C1.CCOC(=O)[C@H]1N[C@@H]2CC[C@H]1C2.C[C@@H](N)C1=CC=CC=C1.C[Pd].O=C(O)[C@@H]1[C@H]2CC[C@H](C2)N1C(=O)OCC1=CC=CC=C1 ITRCGRGACDBFSX-WBLBOCGKSA-N 0.000 description 1
- ZHPXKMMMBHHKIA-UHFFFAOYSA-N CNC1=CN=C2CCC(C(C)=O)N2C1=O.CNC1=CN=C2CCCC(C(C)=O)N2C1=O.CNC1CCC2CCC(C(C)=O)N2C1.CNC1CCC2OCC(C(C)=O)N2C1.CNC1CCCN2CCC(C(C)=O)N2C1=O.CNC1CCCN2CCCC(C(C)=O)N2C1=O.CNC1CCN2CCC(C(C)=O)N2C1=O.CNC1CCN2CCCC(C(C)=O)N2C1=O.CNC1CN2CCC(C(C)=O)N2C1=O.CNC1CN2CCCC(C(C)=O)N2C1=O.CNN1CCCN2CCC(C(C)=O)N2C1=O.CNN1CCCN2CCCC(C(C)=O)N2C1=O.CNN1CCN2CCC(C(C)=O)N2C1=O.CNN1CCN2CCCC(C(C)=O)N2C1=O.CNN1CN2CCC(C(C)=O)N2C1=O.CNN1CN2CCCC(C(C)=O)N2C1=O Chemical compound CNC1=CN=C2CCC(C(C)=O)N2C1=O.CNC1=CN=C2CCCC(C(C)=O)N2C1=O.CNC1CCC2CCC(C(C)=O)N2C1.CNC1CCC2OCC(C(C)=O)N2C1.CNC1CCCN2CCC(C(C)=O)N2C1=O.CNC1CCCN2CCCC(C(C)=O)N2C1=O.CNC1CCN2CCC(C(C)=O)N2C1=O.CNC1CCN2CCCC(C(C)=O)N2C1=O.CNC1CN2CCC(C(C)=O)N2C1=O.CNC1CN2CCCC(C(C)=O)N2C1=O.CNN1CCCN2CCC(C(C)=O)N2C1=O.CNN1CCCN2CCCC(C(C)=O)N2C1=O.CNN1CCN2CCC(C(C)=O)N2C1=O.CNN1CCN2CCCC(C(C)=O)N2C1=O.CNN1CN2CCC(C(C)=O)N2C1=O.CNN1CN2CCCC(C(C)=O)N2C1=O ZHPXKMMMBHHKIA-UHFFFAOYSA-N 0.000 description 1
- VRCMKJSMOVNCPC-UHFFFAOYSA-N CNC1C(=O)N2C(C(C)=O)CCC12.CNC1C(=O)N2C(C(C)=O)CCCC12.CNC1C(=O)N2C(C(C)=O)CCOC12.CNC1C(=O)N2C(C(C)=O)CCSC12.CNC1C(=O)N2C(C(C)=O)CNC12.CNC1C(=O)N2C(C(C)=O)COC12.CNC1C(=O)N2C(C(C)=O)CSC12.CNC1CCC2NCC(C(C)=O)N2C1.CNC1CCC2SCC(C(C)=O)N2C1.CNC1CCCN2C(=O)CC(C(C)=O)C12.CNC1CCCN2CC=C(C(C)=O)N2C1=O.CNC1CCCN2CCC=C(C(C)=O)N2C1=O.CNC1CCN2CC=C(C(C)=O)N2C1=O.CNC1CCN2CCC=C(C(C)=O)N2C1=O.CNC1CN2CC=C(C(C)=O)N2C1=O.CNN1CN2CCC=C(C(C)=O)N2C1=O Chemical compound CNC1C(=O)N2C(C(C)=O)CCC12.CNC1C(=O)N2C(C(C)=O)CCCC12.CNC1C(=O)N2C(C(C)=O)CCOC12.CNC1C(=O)N2C(C(C)=O)CCSC12.CNC1C(=O)N2C(C(C)=O)CNC12.CNC1C(=O)N2C(C(C)=O)COC12.CNC1C(=O)N2C(C(C)=O)CSC12.CNC1CCC2NCC(C(C)=O)N2C1.CNC1CCC2SCC(C(C)=O)N2C1.CNC1CCCN2C(=O)CC(C(C)=O)C12.CNC1CCCN2CC=C(C(C)=O)N2C1=O.CNC1CCCN2CCC=C(C(C)=O)N2C1=O.CNC1CCN2CC=C(C(C)=O)N2C1=O.CNC1CCN2CCC=C(C(C)=O)N2C1=O.CNC1CN2CC=C(C(C)=O)N2C1=O.CNN1CN2CCC=C(C(C)=O)N2C1=O VRCMKJSMOVNCPC-UHFFFAOYSA-N 0.000 description 1
- ZSTDCARURLDXSU-UHFFFAOYSA-N CNC1CCC2=CC=CC3=C2N(C1=O)C(C(C)=O)C3.CNC1CCC2CCCC3CC(C(C)=O)N(C1=O)C23.CNC1CCCC2CNCC(C(C)=O)N2C1=O Chemical compound CNC1CCC2=CC=CC3=C2N(C1=O)C(C(C)=O)C3.CNC1CCC2CCCC3CC(C(C)=O)N(C1=O)C23.CNC1CCCC2CNCC(C(C)=O)N2C1=O ZSTDCARURLDXSU-UHFFFAOYSA-N 0.000 description 1
- FZKROWRZRRDLNR-UHFFFAOYSA-N COC(=O)C1CC(=O)CN1C(=O)OCC1=CC=CC=C1.COC(=O)C1CC(F)(F)CN1C(=O)OCC1=CC=CC=C1.ClCCl.O=C(O)C1CC(F)(F)CN1C(=O)OCC1=CC=CC=C1 Chemical compound COC(=O)C1CC(=O)CN1C(=O)OCC1=CC=CC=C1.COC(=O)C1CC(F)(F)CN1C(=O)OCC1=CC=CC=C1.ClCCl.O=C(O)C1CC(F)(F)CN1C(=O)OCC1=CC=CC=C1 FZKROWRZRRDLNR-UHFFFAOYSA-N 0.000 description 1
- JBPUGFODGPKTDW-SFHVURJKSA-N COC1=CC(NC(=O)NC2=CC(CNC(=O)O[C@H]3CCOC3)=CC=C2)=CC=C1C1=CN=CO1 Chemical compound COC1=CC(NC(=O)NC2=CC(CNC(=O)O[C@H]3CCOC3)=CC=C2)=CC=C1C1=CN=CO1 JBPUGFODGPKTDW-SFHVURJKSA-N 0.000 description 1
- UZJDFSPUILCILD-UHFFFAOYSA-N COC1=CC2=C(C=C1)C(OC1CC(C(C)(C)C)N(C(C)(C)C)C1)=CC(C1=CC=CC=C1)=N2.COC1=CC2=C(C=C1)C(OC1CC(C(C)(C)C)N(C(C)(C)C)C1)=CC(C1=CSC(NC(C)=O)=N1)=N2.COC1=CC2=C(C=C1)C(OC1CC(C(C)(C)C)N(C(C)(C)C)C1)=CC(C1=CSC(NC(C)C)=N1)=N2 Chemical compound COC1=CC2=C(C=C1)C(OC1CC(C(C)(C)C)N(C(C)(C)C)C1)=CC(C1=CC=CC=C1)=N2.COC1=CC2=C(C=C1)C(OC1CC(C(C)(C)C)N(C(C)(C)C)C1)=CC(C1=CSC(NC(C)=O)=N1)=N2.COC1=CC2=C(C=C1)C(OC1CC(C(C)(C)C)N(C(C)(C)C)C1)=CC(C1=CSC(NC(C)C)=N1)=N2 UZJDFSPUILCILD-UHFFFAOYSA-N 0.000 description 1
- ZYZMKLAOXHZVFC-UHFFFAOYSA-N [H]N(C(=O)C(=O)N([H])C(C)(C)C)C(C)C.[H]N(C(=O)C(=O)N([H])C(C)(C)C)C1=CC=CC=C1.[H]N(C(=O)C(=O)N([H])C(C)(C)C)C1=NOC(C)=C1.[H]N(C(=O)C(=O)N([H])C(C)(C)C)C1CC1.[H]N(C(=O)C(=O)N([H])C(C)(C)C)C1CCCC1.[H]N(C(=O)C(=O)N([H])C(C)(C)C)C1CCCCC1.[H]N(CC(C)C)C(=O)C(=O)N([H])C(C)(C)C.[H]N(CC1=CC=CC=C1)C(=O)C(=O)N([H])C(C)(C)C.[H]N(CC1CCCCC1)C(=O)C(=O)N([H])C(C)(C)C Chemical compound [H]N(C(=O)C(=O)N([H])C(C)(C)C)C(C)C.[H]N(C(=O)C(=O)N([H])C(C)(C)C)C1=CC=CC=C1.[H]N(C(=O)C(=O)N([H])C(C)(C)C)C1=NOC(C)=C1.[H]N(C(=O)C(=O)N([H])C(C)(C)C)C1CC1.[H]N(C(=O)C(=O)N([H])C(C)(C)C)C1CCCC1.[H]N(C(=O)C(=O)N([H])C(C)(C)C)C1CCCCC1.[H]N(CC(C)C)C(=O)C(=O)N([H])C(C)(C)C.[H]N(CC1=CC=CC=C1)C(=O)C(=O)N([H])C(C)(C)C.[H]N(CC1CCCCC1)C(=O)C(=O)N([H])C(C)(C)C ZYZMKLAOXHZVFC-UHFFFAOYSA-N 0.000 description 1
- ZGXJIZJJHROEFQ-UHFFFAOYSA-N [H]N1C(=O)C=CC=C1C(C)(C)C.[H]N1C(=O)CC(=O)C=C1C(C)(C)C.[H]N1C(=O)CC(=O)CC1C(C)(C)C.[H]N1C(=O)CC(=O)NC1C(C)(C)C.[H]N1C(=O)CCC1C(C)(C)C.[H]N1C(=O)CCCC1C(C)(C)C.[H]N1C(=O)NCC1C(C)(C)C.[H]N1C(=O)OCC1C(C)(C)C.[H]N1C(=O)SCC1C(C)(C)C.[H]N1C(C(C)(C)C)CNS1(=O)=O.[H]N1C(C(C)(C)C)CNS1=O.[H]N1C(C)=C(C)C(C(C)=O)=C1C(C)(C)C.[H]N1C=CC=C1C(C)(C)C.[H]N1C=CN=C1C(C)(C)C.[H]N1N=CC=C1C(C)(C)C.[H]N1N=NN=C1C(C)(C)C Chemical compound [H]N1C(=O)C=CC=C1C(C)(C)C.[H]N1C(=O)CC(=O)C=C1C(C)(C)C.[H]N1C(=O)CC(=O)CC1C(C)(C)C.[H]N1C(=O)CC(=O)NC1C(C)(C)C.[H]N1C(=O)CCC1C(C)(C)C.[H]N1C(=O)CCCC1C(C)(C)C.[H]N1C(=O)NCC1C(C)(C)C.[H]N1C(=O)OCC1C(C)(C)C.[H]N1C(=O)SCC1C(C)(C)C.[H]N1C(C(C)(C)C)CNS1(=O)=O.[H]N1C(C(C)(C)C)CNS1=O.[H]N1C(C)=C(C)C(C(C)=O)=C1C(C)(C)C.[H]N1C=CC=C1C(C)(C)C.[H]N1C=CN=C1C(C)(C)C.[H]N1N=CC=C1C(C)(C)C.[H]N1N=NN=C1C(C)(C)C ZGXJIZJJHROEFQ-UHFFFAOYSA-N 0.000 description 1
- HGGFUNUUWODVSD-UHFFFAOYSA-N [H]N1C(=O)C=CC=C1C(C)(C)C.[H]N1C(=O)CC(=O)cc1C(C)(C)C.[H]N1C(=O)CC(=O)cc1C(C)(C)C.[H]N1C(=O)CCCC1C(C)(C)C.[H]N1C(=O)cc-cc1C(C)(C)C.[H]N1C(C(C)(C)C)CNS1=O.[H]N1C(C)=C(C)C(C(C)=O)=C1C(C)(C)C.[H]N1C=CC=C1C(C)(C)C.[H]N1C=CN=C1C(C)(C)C.[H]N1C=NC=C1C(C)(C)C.[H]N1C=NN=C1C(C)(C)C.[H]N1N=CC=C1C(C)(C)C.[H]N1N=CN=C1C(C)(C)C.[H]N1N=NC=C1C(C)(C)C.[H]N1N=NN=C1C(C)(C)C.[H]N1c(C(C)(C)C)c-ccS1(=O)=O.[H]N1c(C(C)(C)C)c-ccS1=O.[H]N1c(C(C)(C)C)cC(=O)CS1(=O)=O.[H]N1c(C(C)(C)C)cC(=O)CS1=O.[H]N1c(C(C)(C)C)cC(=O)CS1=O Chemical compound [H]N1C(=O)C=CC=C1C(C)(C)C.[H]N1C(=O)CC(=O)cc1C(C)(C)C.[H]N1C(=O)CC(=O)cc1C(C)(C)C.[H]N1C(=O)CCCC1C(C)(C)C.[H]N1C(=O)cc-cc1C(C)(C)C.[H]N1C(C(C)(C)C)CNS1=O.[H]N1C(C)=C(C)C(C(C)=O)=C1C(C)(C)C.[H]N1C=CC=C1C(C)(C)C.[H]N1C=CN=C1C(C)(C)C.[H]N1C=NC=C1C(C)(C)C.[H]N1C=NN=C1C(C)(C)C.[H]N1N=CC=C1C(C)(C)C.[H]N1N=CN=C1C(C)(C)C.[H]N1N=NC=C1C(C)(C)C.[H]N1N=NN=C1C(C)(C)C.[H]N1c(C(C)(C)C)c-ccS1(=O)=O.[H]N1c(C(C)(C)C)c-ccS1=O.[H]N1c(C(C)(C)C)cC(=O)CS1(=O)=O.[H]N1c(C(C)(C)C)cC(=O)CS1=O.[H]N1c(C(C)(C)C)cC(=O)CS1=O HGGFUNUUWODVSD-UHFFFAOYSA-N 0.000 description 1
- CUPQWVCNZYVNLA-UHFFFAOYSA-N [H]N1C(=O)CC(=O)cc1C(C)(C)C.[H]N1C(=O)CC(=O)cc1C(C)(C)C.[H]N1C(=O)CCC1C(C)(C)C.[H]N1C(=O)NCC1C(C)(C)C.[H]N1C(=O)OCC1C(C)(C)C.[H]N1C(=O)SCC1C(C)(C)C.[H]N1C(C(C)(C)C)=CC(Cl)=C1Cl.[H]N1C(C(C)(C)C)CNS1(=O)=O.[H]N1C(C(C)(C)C)CNS1=O.[H]N1C(C)=C(C)C(C(C)=O)=C1C(C)(C)C.[H]N1C=CC=C1C(C)(C)C.[H]N1C=CN=C1C(C)(C)C.[H]N1C=NC=C1C(C)(C)C.[H]N1C=NN=C1C(C)(C)C.[H]N1N=CC=C1C(C)(C)C.[H]N1N=CC=C1C(C)(C)C.[H]N1N=NN=C1C(C)(C)C.[H]N1c(C(C)(C)C)cC(=O)CS1(=O)=O.[H]N1c(C(C)(C)C)cC(=O)CS1=O.[H]N1c(C(C)(C)C)cC(=O)CS1=O Chemical compound [H]N1C(=O)CC(=O)cc1C(C)(C)C.[H]N1C(=O)CC(=O)cc1C(C)(C)C.[H]N1C(=O)CCC1C(C)(C)C.[H]N1C(=O)NCC1C(C)(C)C.[H]N1C(=O)OCC1C(C)(C)C.[H]N1C(=O)SCC1C(C)(C)C.[H]N1C(C(C)(C)C)=CC(Cl)=C1Cl.[H]N1C(C(C)(C)C)CNS1(=O)=O.[H]N1C(C(C)(C)C)CNS1=O.[H]N1C(C)=C(C)C(C(C)=O)=C1C(C)(C)C.[H]N1C=CC=C1C(C)(C)C.[H]N1C=CN=C1C(C)(C)C.[H]N1C=NC=C1C(C)(C)C.[H]N1C=NN=C1C(C)(C)C.[H]N1N=CC=C1C(C)(C)C.[H]N1N=CC=C1C(C)(C)C.[H]N1N=NN=C1C(C)(C)C.[H]N1c(C(C)(C)C)cC(=O)CS1(=O)=O.[H]N1c(C(C)(C)C)cC(=O)CS1=O.[H]N1c(C(C)(C)C)cC(=O)CS1=O CUPQWVCNZYVNLA-UHFFFAOYSA-N 0.000 description 1
- LSIBPJXIJAXYHM-UHFFFAOYSA-N [H]N1C(=O)CCC1C(C)(C)C.[H]N1C(=O)NCC1C(C)(C)C.[H]N1C(=O)OCC1C(C)(C)C.[H]N1C(=O)SCC1C(C)(C)C.[H]N1C(C(C)(C)C)=CC(Cl)=C1Cl.[H]N1C=CN=C1C(C)(C)C.[H]N1N=NN=C1C(C)(C)C Chemical compound [H]N1C(=O)CCC1C(C)(C)C.[H]N1C(=O)NCC1C(C)(C)C.[H]N1C(=O)OCC1C(C)(C)C.[H]N1C(=O)SCC1C(C)(C)C.[H]N1C(C(C)(C)C)=CC(Cl)=C1Cl.[H]N1C=CN=C1C(C)(C)C.[H]N1N=NN=C1C(C)(C)C LSIBPJXIJAXYHM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Hydrogenated Pyridines (AREA)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/964,214 US7208600B2 (en) | 2003-10-10 | 2004-10-12 | Inhibitors of serine proteases, particularly HCV NS3-NS4A proteases |
| US11/716,248 US8039623B2 (en) | 2003-10-10 | 2007-03-09 | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US51015603P | 2003-10-10 | 2003-10-10 | |
| US51376803P | 2003-10-23 | 2003-10-23 | |
| US10/964,214 US7208600B2 (en) | 2003-10-10 | 2004-10-12 | Inhibitors of serine proteases, particularly HCV NS3-NS4A proteases |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US11/716,248 Continuation US8039623B2 (en) | 2003-10-10 | 2007-03-09 | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| US20050137140A1 US20050137140A1 (en) | 2005-06-23 |
| US7208600B2 true US7208600B2 (en) | 2007-04-24 |
Family
ID=34467967
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US10/964,214 Expired - Fee Related US7208600B2 (en) | 2003-10-10 | 2004-10-12 | Inhibitors of serine proteases, particularly HCV NS3-NS4A proteases |
| US11/716,248 Expired - Fee Related US8039623B2 (en) | 2003-10-10 | 2007-03-09 | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US11/716,248 Expired - Fee Related US8039623B2 (en) | 2003-10-10 | 2007-03-09 | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease |
Country Status (14)
Cited By (74)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030236242A1 (en) * | 2000-04-03 | 2003-12-25 | Robert Perni | Inhibitors of serine proteases, particularly hepatitis C virus NS3 protease |
| US20050080017A1 (en) * | 2003-10-10 | 2005-04-14 | Cottrell Kevin M. | Inhibitors of serine proteases, particularly HVC NS3-NS4A protease |
| US20050197299A1 (en) * | 2000-08-31 | 2005-09-08 | Babine Robert E. | Peptidomimetic protease inhibitors |
| US20050215486A1 (en) * | 2004-02-04 | 2005-09-29 | Kevin Cottrell | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease |
| US20060003942A1 (en) * | 2003-10-27 | 2006-01-05 | Roger Tung | Combinations for HCV treatment |
| US20060211629A1 (en) * | 2003-07-18 | 2006-09-21 | Britt Shawn D | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease |
| US20070054842A1 (en) * | 2005-07-25 | 2007-03-08 | Blatt Lawrence M | Novel macrocyclic inhibitors of hepatitis C virus replication |
| US20070161789A1 (en) * | 2003-10-10 | 2007-07-12 | Cottrell Kevin M | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease |
| US20070179167A1 (en) * | 2005-08-26 | 2007-08-02 | Cottrell Kevin M | Inhibitors of serine proteases |
| US20080019942A1 (en) * | 2006-07-05 | 2008-01-24 | Intermune, Inc | Novel inhibitors of hepatitis c virus replication |
| US20080311079A1 (en) * | 2003-09-05 | 2008-12-18 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease |
| US7491794B2 (en) | 2003-10-14 | 2009-02-17 | Intermune, Inc. | Macrocyclic compounds as inhibitors of viral replication |
| US20090104001A1 (en) * | 2007-10-19 | 2009-04-23 | Kochheiser Michael A | Non-dimpling fastener |
| US20090143312A1 (en) * | 1996-10-18 | 2009-06-04 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease |
| US20090155209A1 (en) * | 2007-05-03 | 2009-06-18 | Blatt Lawrence M | Novel macrocyclic inhibitors of hepatitis c virus replication |
| US20090176858A1 (en) * | 2007-12-21 | 2009-07-09 | Avila Therapeutics, Inc. | Hcv protease inhibitors and uses thereof |
| WO2009099596A2 (en) | 2008-02-04 | 2009-08-13 | Idenix Pharamaceuticals, Inc. | Macrocyclic serine protease inhibitors |
| US20090269305A1 (en) * | 2008-04-15 | 2009-10-29 | Intermune, Inc. | Novel macrocyclic inhibitors of hepatitis c virus replication |
| US20100069294A1 (en) * | 2007-12-21 | 2010-03-18 | Avila Therapeutics, Inc. | Hcv protease inhibitors and uses thereof |
| US20100169022A1 (en) * | 2008-12-30 | 2010-07-01 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Computational methods and systems for treatment in relation to modulation of CYP450 enzyme activity |
| US20100195379A1 (en) * | 2009-02-02 | 2010-08-05 | Qualcomm Incorporated | System and Method of Pulse Generation |
| US20100221217A1 (en) * | 2009-02-27 | 2010-09-02 | Intermune, Inc. | Therapeutic composition |
| WO2010101967A2 (en) | 2009-03-04 | 2010-09-10 | Idenix Pharmaceuticals, Inc. | Phosphothiophene and phosphothiazole hcv polymerase inhibitors |
| US20100272681A1 (en) * | 2007-02-27 | 2010-10-28 | Vertex Pharmaceuticals Incorporated | Inhibitors of Serine Proteases |
| WO2011017389A1 (en) | 2009-08-05 | 2011-02-10 | Idenix Pharmaceuticals, Inc. | Macrocyclic serine protease inhibitors useful against viral infections, particularly hcv |
| US20110081315A1 (en) * | 2009-09-28 | 2011-04-07 | Intermune, Inc. | Novel macrocyclic inhibitors of hepatitis c virus replication |
| US7932277B2 (en) | 2007-05-10 | 2011-04-26 | Intermune, Inc. | Peptide inhibitors of hepatitis C virus replication |
| WO2011063076A1 (en) | 2009-11-19 | 2011-05-26 | Itherx Pharmaceuticals, Inc. | Methods of treating hepatitis c virus with oxoacetamide compounds |
| US7964624B1 (en) | 2005-08-26 | 2011-06-21 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases |
| WO2011075615A1 (en) | 2009-12-18 | 2011-06-23 | Idenix Pharmaceuticals, Inc. | 5,5-fused arylene or heteroarylene hepatitis c virus inhibitors |
| US20110171175A1 (en) * | 2005-08-02 | 2011-07-14 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases |
| WO2011123586A1 (en) | 2010-04-01 | 2011-10-06 | Idenix Pharmaceuticals, Inc. | Compounds and pharmaceutical compositions for the treatment of viral infections |
| US8119592B2 (en) | 2005-10-11 | 2012-02-21 | Intermune, Inc. | Compounds and methods for inhibiting hepatitis C viral replication |
| EP2476690A1 (en) | 2008-07-02 | 2012-07-18 | IDENIX Pharmaceuticals, Inc. | Compounds and pharmaceutical compositions for the treatment of viral infections |
| WO2012109398A1 (en) | 2011-02-10 | 2012-08-16 | Idenix Pharmaceuticals, Inc. | Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating hcv infections |
| US8247532B2 (en) | 2006-03-16 | 2012-08-21 | Vertex Pharmaceuticals Incorporated | Deuterated hepatitis C protease inhibitors |
| WO2012135581A1 (en) | 2011-03-31 | 2012-10-04 | Idenix Pharmaceuticals, Inc. | Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor |
| US8293705B2 (en) | 2007-12-21 | 2012-10-23 | Avila Therapeutics, Inc. | HCV protease inhibitors and uses thereof |
| WO2012154321A1 (en) | 2011-03-31 | 2012-11-15 | Idenix Pharmaceuticals, Inc. | Compounds and pharmaceutical compositions for the treatment of viral infections |
| US8315815B2 (en) | 2008-12-30 | 2012-11-20 | The Invention Science Fund I, Llc | Computational methods and systems for suggesting modulators of CYP450 as treatment options |
| US8321151B2 (en) | 2008-12-30 | 2012-11-27 | The Invention Science Fund I, Llc | Computational methods and systems for treatment in relation to modulation of CYP450 enzyme activity |
| US8377962B2 (en) | 2009-04-08 | 2013-02-19 | Idenix Pharmaceuticals, Inc. | Macrocyclic serine protease inhibitors |
| WO2013039920A1 (en) | 2011-09-12 | 2013-03-21 | Idenix Pharmaceuticals, Inc. | Substituted carbonyloxymethylphosphoramidate compounds and pharmaceutical compositions for the treatment of viral infections |
| WO2013039855A1 (en) | 2011-09-12 | 2013-03-21 | Idenix Pharmaceuticals, Inc. | Compounds and pharmaceutical compositions for the treatment of viral infections |
| WO2013056046A1 (en) | 2011-10-14 | 2013-04-18 | Idenix Pharmaceuticals, Inc. | Substituted 3',5'-cyclic phosphates of purine nucleotide compounds and pharmaceutical compositions for the treatment of viral infections |
| WO2013133927A1 (en) | 2012-02-13 | 2013-09-12 | Idenix Pharmaceuticals, Inc. | Pharmaceutical compositions of 2'-c-methyl-guanosine, 5'-[2-[(3-hydroxy-2,2-dimethyl-1-oxopropyl)thio]ethyl n-(phenylmethyl)phosphoramidate] |
| WO2013177188A1 (en) | 2012-05-22 | 2013-11-28 | Idenix Pharmaceuticals, Inc. | 3',5'-cyclic phosphoramidate prodrugs for hcv infection |
| WO2013177219A1 (en) | 2012-05-22 | 2013-11-28 | Idenix Pharmaceuticals, Inc. | D-amino acid compounds for liver disease |
| WO2013177195A1 (en) | 2012-05-22 | 2013-11-28 | Idenix Pharmaceuticals, Inc. | 3',5'-cyclic phosphate prodrugs for hcv infection |
| WO2014058801A1 (en) | 2012-10-08 | 2014-04-17 | Idenix Pharmaceuticals, Inc. | 2'-chloro nucleoside analogs for hcv infection |
| WO2014063019A1 (en) | 2012-10-19 | 2014-04-24 | Idenix Pharmaceuticals, Inc. | Dinucleotide compounds for hcv infection |
| WO2014066239A1 (en) | 2012-10-22 | 2014-05-01 | Idenix Pharmaceuticals, Inc. | 2',4'-bridged nucleosides for hcv infection |
| WO2014078436A1 (en) | 2012-11-14 | 2014-05-22 | Idenix Pharmaceuticals, Inc. | D-alanine ester of sp-nucleoside analog |
| WO2014078427A1 (en) | 2012-11-14 | 2014-05-22 | Idenix Pharmaceuticals, Inc. | D-alanine ester of rp-nucleoside analog |
| WO2014099941A1 (en) | 2012-12-19 | 2014-06-26 | Idenix Pharmaceuticals, Inc. | 4'-fluoro nucleosides for the treatment of hcv |
| WO2014137930A1 (en) | 2013-03-04 | 2014-09-12 | Idenix Pharmaceuticals, Inc. | Thiophosphate nucleosides for the treatment of hcv |
| WO2014137926A1 (en) | 2013-03-04 | 2014-09-12 | Idenix Pharmaceuticals, Inc. | 3'-deoxy nucleosides for the treatment of hcv |
| WO2014165542A1 (en) | 2013-04-01 | 2014-10-09 | Idenix Pharmaceuticals, Inc. | 2',4'-fluoro nucleosides for the treatment of hcv |
| US8871904B2 (en) | 2005-08-19 | 2014-10-28 | Vertex Pharmaceuticals Incorporated | Processes and intermediates |
| WO2014197578A1 (en) | 2013-06-05 | 2014-12-11 | Idenix Pharmaceuticals, Inc. | 1',4'-thio nucleosides for the treatment of hcv |
| WO2015017713A1 (en) | 2013-08-01 | 2015-02-05 | Idenix Pharmaceuticals, Inc. | D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease |
| WO2015042375A1 (en) | 2013-09-20 | 2015-03-26 | Idenix Pharmaceuticals, Inc. | Hepatitis c virus inhibitors |
| WO2015061683A1 (en) | 2013-10-25 | 2015-04-30 | Idenix Pharmaceuticals, Inc. | D-amino acid phosphoramidate and d-alanine thiophosphoramidate pronucleotides of nucleoside compounds useful for the treatment of hcv |
| WO2015066370A1 (en) | 2013-11-01 | 2015-05-07 | Idenix Pharmaceuticals, Inc. | D-alanine phosphoramidate pronucleotides of 2'-methyl 2'-fluoro guanosine nucleoside compounds for the treatment of hcv |
| WO2015081297A1 (en) | 2013-11-27 | 2015-06-04 | Idenix Pharmaceuticals, Inc. | 2'-dichloro and 2'-fluoro-2'-chloro nucleoside analogues for hcv infection |
| WO2015095419A1 (en) | 2013-12-18 | 2015-06-25 | Idenix Pharmaceuticals, Inc. | 4'-or nucleosides for the treatment of hcv |
| WO2015134560A1 (en) | 2014-03-05 | 2015-09-11 | Idenix Pharmaceuticals, Inc. | Solid forms of a flaviviridae virus inhibitor compound and salts thereof |
| WO2015134561A1 (en) | 2014-03-05 | 2015-09-11 | Idenix Pharmaceuticals, Inc. | Pharmaceutical compositions comprising a 5,5-fused heteroarylene flaviviridae inhibitor and their use for treating or preventing flaviviridae infection |
| WO2015134780A1 (en) | 2014-03-05 | 2015-09-11 | Idenix Pharmaceuticals, Inc. | Solid prodrug forms of 2'-chloro-2'-methyl uridine for hcv |
| US9163061B2 (en) | 2007-12-21 | 2015-10-20 | Celgene Avilomics Research, Inc. | HCV protease inhibitors and uses thereof |
| WO2015161137A1 (en) | 2014-04-16 | 2015-10-22 | Idenix Pharmaceuticals, Inc. | 3'-substituted methyl or alkynyl nucleosides for the treatment of hcv |
| US9815850B2 (en) | 2016-02-05 | 2017-11-14 | Denali Therapeutics Inc. | Compounds, compositions and methods |
| EP3750544A2 (en) | 2011-11-30 | 2020-12-16 | Emory University | Jak inhibitors for use in the prevention or treatment of viral infection |
| US11072618B2 (en) | 2016-12-09 | 2021-07-27 | Denali Therapeutics Inc. | Compounds, compositions and methods |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY140680A (en) | 2002-05-20 | 2010-01-15 | Bristol Myers Squibb Co | Hepatitis c virus inhibitors |
| US7176208B2 (en) | 2003-04-18 | 2007-02-13 | Enanta Pharmaceuticals, Inc. | Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors |
| EP1664091A1 (en) | 2003-09-18 | 2006-06-07 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases, particularly hcv ns3-ns4a protease |
| US7323447B2 (en) | 2005-02-08 | 2008-01-29 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7592336B2 (en) | 2005-05-10 | 2009-09-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7601686B2 (en) | 2005-07-11 | 2009-10-13 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7772183B2 (en) | 2005-10-12 | 2010-08-10 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7741281B2 (en) | 2005-11-03 | 2010-06-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| JP5436864B2 (ja) | 2006-02-27 | 2014-03-05 | バーテックス ファーマシューティカルズ インコーポレイテッド | Ｖｘ−９５０を含む共結晶体およびそれを含む医薬組成物 |
| ES2543840T3 (es) * | 2006-04-11 | 2015-08-24 | Novartis Ag | Inhibidores espirocíclicos del VHC/VIH y sus usos |
| BRPI0712021A2 (pt) | 2006-05-23 | 2012-01-03 | Irm Llc | composto e composiÇÕes como inibidores da protease ativadora de canal |
| WO2008008776A2 (en) | 2006-07-11 | 2008-01-17 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| US8343477B2 (en) | 2006-11-01 | 2013-01-01 | Bristol-Myers Squibb Company | Inhibitors of hepatitis C virus |
| US7772180B2 (en) | 2006-11-09 | 2010-08-10 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7888464B2 (en) | 2006-11-16 | 2011-02-15 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7763584B2 (en) | 2006-11-16 | 2010-07-27 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8003604B2 (en) | 2006-11-16 | 2011-08-23 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| CN101600428A (zh) | 2007-02-09 | 2009-12-09 | Irm责任有限公司 | 作为通道活化蛋白酶抑制剂的化合物和组合物 |
| ES2379905T3 (es) | 2007-02-27 | 2012-05-04 | Vertex Pharmceuticals Incorporated | Co-cristales y composiciones farmacéuticas que los comprenden |
| CL2008002549A1 (es) | 2007-08-30 | 2010-09-03 | Vertex Pharma | Cocristal que comprende vx-950 y un formador de cocristal seleccionado de acido 3-metoxi-4hidroxibenzoico,acido 2,4-dihidroxibenzoico y acido 2,5-dihidroxibenzoico; metodo de preparacion; composicion farmaceutica que comprende el cocristal, util como agente antiviral en el tratamiento del hcv. |
| US8202996B2 (en) | 2007-12-21 | 2012-06-19 | Bristol-Myers Squibb Company | Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide |
| US8101567B2 (en) * | 2008-01-24 | 2012-01-24 | Enanta Pharmaceuticals, Inc. | Heteroaryl-containing tripeptide HCV serine protease inhibitors |
| US8163921B2 (en) | 2008-04-16 | 2012-04-24 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7964560B2 (en) | 2008-05-29 | 2011-06-21 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| JP5529120B2 (ja) | 2008-05-29 | 2014-06-25 | ブリストル−マイヤーズ スクイブ カンパニー | Ｃ型肝炎ウイルス阻害剤 |
| US8207341B2 (en) | 2008-09-04 | 2012-06-26 | Bristol-Myers Squibb Company | Process or synthesizing substituted isoquinolines |
| US8044087B2 (en) | 2008-09-29 | 2011-10-25 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8563505B2 (en) | 2008-09-29 | 2013-10-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| EA201170441A1 (ru) * | 2008-10-15 | 2012-05-30 | Интермьюн, Инк. | Терапевтические противовирусные пептиды |
| US8283310B2 (en) | 2008-12-15 | 2012-10-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8512690B2 (en) | 2009-04-10 | 2013-08-20 | Novartis Ag | Derivatised proline containing peptide compounds as protease inhibitors |
| US20110182850A1 (en) * | 2009-04-10 | 2011-07-28 | Trixi Brandl | Organic compounds and their uses |
| TW201116540A (en) * | 2009-10-01 | 2011-05-16 | Intermune Inc | Therapeutic antiviral peptides |
| US8957203B2 (en) | 2011-05-05 | 2015-02-17 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8691757B2 (en) | 2011-06-15 | 2014-04-08 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| MX360452B (es) | 2012-10-19 | 2018-11-01 | Bristol Myers Squibb Co | Inhibidores del virus de la hepatitis c. |
| US9598433B2 (en) | 2012-11-02 | 2017-03-21 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US9643999B2 (en) | 2012-11-02 | 2017-05-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| WO2014071007A1 (en) | 2012-11-02 | 2014-05-08 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| WO2014070974A1 (en) | 2012-11-05 | 2014-05-08 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| WO2014137869A1 (en) | 2013-03-07 | 2014-09-12 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| EP2899207A1 (en) | 2014-01-28 | 2015-07-29 | Amikana.Biologics | New method for testing HCV protease inhibition |
| WO2016129983A1 (en) * | 2015-02-13 | 2016-08-18 | Latvian Institute Of Organic Synthesis | Novel n-acyl-arylsulfonamide derivatives as aminoacyl-trna synthetase inhibitors |
| GB201617064D0 (en) | 2016-10-07 | 2016-11-23 | Inhibox Limited And Latvian Institute Of Organic Synthesis The | Compounds and their therapeutic use |
| JP2022510407A (ja) | 2018-12-04 | 2022-01-26 | ブリストル－マイヤーズ スクイブ カンパニー | 多重反応同位体分子種反応モニタリングによる、サンプル内検量線を用いた分析方法 |
Citations (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994014436A1 (en) | 1992-12-29 | 1994-07-07 | Abbott Laboratories | Retroviral protease inhibiting compounds |
| WO1995007696A1 (en) | 1993-09-13 | 1995-03-23 | Abbott Laboratories | Pharmaceutical composition of hiv-protease inhibitors |
| WO1995009614A1 (en) | 1993-10-01 | 1995-04-13 | Abbott Laboratories | Pharmaceutical composition |
| EP0675112A1 (en) | 1994-03-31 | 1995-10-04 | Bristol-Myers Squibb Company | Imidazole-containing inhibitors of farnesyl protein transferase |
| US5484801A (en) | 1994-01-28 | 1996-01-16 | Abbott Laboratories | Pharmaceutical composition for inhibiting HIV protease |
| WO1997040028A1 (en) | 1996-04-23 | 1997-10-30 | Vertex Pharmaceuticals Incorporated | Urea derivatives as inhibitors of impdh enzyme |
| WO1998017679A1 (en) | 1996-10-18 | 1998-04-30 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease |
| US5807876A (en) | 1996-04-23 | 1998-09-15 | Vertex Pharmaceuticals Incorporated | Inhibitors of IMPDH enzyme |
| WO1998040381A1 (en) | 1997-03-14 | 1998-09-17 | Vertex Pharmaceuticals Incorporated | Inhibitors of impdh enzyme |
| US6037157A (en) | 1995-06-29 | 2000-03-14 | Abbott Laboratories | Method for improving pharmacokinetics |
| US6054472A (en) | 1996-04-23 | 2000-04-25 | Vertex Pharmaceuticals, Incorporated | Inhibitors of IMPDH enzyme |
| WO2000056331A1 (en) | 1999-03-19 | 2000-09-28 | Vertex Pharmaceuticals Incorporated | Inhibitors of impdh enzyme |
| WO2002008244A2 (en) | 2000-07-21 | 2002-01-31 | Schering Corporation | Peptides as ns3-serine protease inhibitors of hepatitis c virus |
| WO2002018369A2 (en) | 2000-08-31 | 2002-03-07 | Eli Lilly And Company | Peptidomimetic protease inhibitors |
| WO2003006490A1 (en) | 2001-07-11 | 2003-01-23 | Vertex Pharmaceuticals Incorporated | Bridged bicyclic serine protease inhibitors |
| WO2003035060A1 (en) | 2001-10-24 | 2003-05-01 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine protease, particularly hepatitis c virus ns3-ns4a protease, incorporating a fused ring system |
| WO2003087092A2 (en) | 2002-04-11 | 2003-10-23 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases, particularly hepatitis c virus ns3 - ns4 protease |
| WO2004092161A1 (en) | 2003-04-11 | 2004-10-28 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases, particularly hcv ns3-ns4a protease |
| WO2004092612A1 (de) | 2003-04-04 | 2004-10-28 | Zf Boge Elastmetall Gmbh | Hydraulisch dämpfendes gummibuchsenlager für vertikale montage |
| US7109172B2 (en) * | 2003-07-18 | 2006-09-19 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2933797A (en) | 1996-05-10 | 1997-12-05 | Schering Corporation | Synthetic inhibitors of hepatitis c virus ns3 protease |
| GB9623908D0 (en) | 1996-11-18 | 1997-01-08 | Hoffmann La Roche | Amino acid derivatives |
| GB9707659D0 (en) | 1997-04-16 | 1997-06-04 | Peptide Therapeutics Ltd | Hepatitis C NS3 Protease inhibitors |
| ES2241157T3 (es) | 1997-08-11 | 2005-10-16 | Boehringer Ingelheim (Canada) Ltd. | Peptidos inhibidores de la hepatitis c. |
| EP1012180B1 (en) | 1997-08-11 | 2004-12-01 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis c inhibitor peptide analogues |
| IT1299134B1 (it) | 1998-02-02 | 2000-02-29 | Angeletti P Ist Richerche Bio | Procedimento per la produzione di peptidi con proprieta' inibitrici della proteasi ns3 del virus hcv, peptidi cosi' ottenibili e peptidi |
| ES2281170T3 (es) | 1998-03-31 | 2007-09-16 | Vertex Pharmaceuticals Incorporated | Inhibidores de serina proteasas, particularmente proteasa ns3 del virus de la hepatitis c. |
| GB9812523D0 (en) | 1998-06-10 | 1998-08-05 | Angeletti P Ist Richerche Bio | Peptide inhibitors of hepatitis c virus ns3 protease |
| US6323180B1 (en) | 1998-08-10 | 2001-11-27 | Boehringer Ingelheim (Canada) Ltd | Hepatitis C inhibitor tri-peptides |
| DE19836514A1 (de) | 1998-08-12 | 2000-02-17 | Univ Stuttgart | Modifikation von Engineeringpolymeren mit N-basischen Gruppe und mit Ionenaustauschergruppen in der Seitenkette |
| GB9825946D0 (en) | 1998-11-26 | 1999-01-20 | Angeletti P Ist Richerche Bio | Pharmaceutical compounds for the inhibition of hepatitis C virus NS3 protease |
| UA74546C2 (en) | 1999-04-06 | 2006-01-16 | Boehringer Ingelheim Ca Ltd | Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition |
| WO2001007407A1 (en) | 1999-07-26 | 2001-02-01 | Bristol-Myers Squibb Pharma Company | Lactam inhibitors of hepatitis c virus ns3 protease |
| US7122627B2 (en) | 1999-07-26 | 2006-10-17 | Bristol-Myers Squibb Company | Lactam inhibitors of Hepatitis C virus NS3 protease |
| WO2001064678A2 (en) | 2000-02-29 | 2001-09-07 | Bristol-Myers Squibb Pharma Company | Inhibitors of hepatitis c virus ns3 protease |
| AU2001251165A1 (en) * | 2000-04-03 | 2001-10-15 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease |
| AR029903A1 (es) | 2000-04-05 | 2003-07-23 | Schering Corp | Inhibidores macrociclicos de la ns3-serina proteasa, del virus de la hepatitis c, que comprenden partes p2 n-ciclicas, composiciones farmaceuticas y utilizacion de los mismos para la manufactura de un medicamento |
| CN1432022A (zh) | 2000-04-19 | 2003-07-23 | 先灵公司 | 含有烷基和芳基丙氨酸p2部分的丙型肝炎病毒的大环ns3－丝氨酸蛋白酶抑制剂 |
| AR034127A1 (es) | 2000-07-21 | 2004-02-04 | Schering Corp | Imidazolidinonas como inhibidores de ns3-serina proteasa del virus de hepatitis c, composicion farmaceutica, un metodo para su preparacion, y el uso de las mismas para la manufactura de un medicamento |
| CZ2003195A3 (cs) | 2000-07-21 | 2003-04-16 | Schering Corporation | Peptidové inhibitory serinové proteázy NS3 a farmaceutický prostředek |
| AR029851A1 (es) | 2000-07-21 | 2003-07-16 | Dendreon Corp | Nuevos peptidos como inhibidores de ns3-serina proteasa del virus de hepatitis c |
| US6846806B2 (en) | 2000-10-23 | 2005-01-25 | Bristol-Myers Squibb Company | Peptide inhibitors of Hepatitis C virus NS3 protein |
| HUP0500456A3 (en) | 2000-11-20 | 2012-05-02 | Bristol Myers Squibb Co | Hepatitis c tripeptide inhibitors, pharmaceutical compositions comprising thereof and their use |
| US6727366B2 (en) | 2000-12-13 | 2004-04-27 | Bristol-Myers Squibb Pharma Company | Imidazolidinones and their related derivatives as hepatitis C virus NS3 protease inhibitors |
| WO2002048116A2 (en) | 2000-12-13 | 2002-06-20 | Bristol-Myers Squibb Pharma Company | Inhibitors of hepatitis c virus ns3 protease |
| GB0107924D0 (en) | 2001-03-29 | 2001-05-23 | Angeletti P Ist Richerche Bio | Inhibitor of hepatitis C virus NS3 protease |
| CA2369970A1 (en) * | 2002-02-01 | 2003-08-01 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis c inhibitor tri-peptides |
| US20050075279A1 (en) * | 2002-10-25 | 2005-04-07 | Boehringer Ingelheim International Gmbh | Macrocyclic peptides active against the hepatitis C virus |
| KR100940619B1 (ko) | 2003-02-07 | 2010-02-05 | 이난타 파마슈티칼스, 인코포레이티드 | 마크로사이클릭 씨형 간염 세린 단백효소 억제제 |
| CA2521678A1 (en) * | 2003-04-11 | 2004-10-28 | Vertex Pharmaceuticals, Incorporated | Inhibitors of serine proteases, particularly hcv ns3-ns4a protease |
| JP2006515360A (ja) | 2003-05-01 | 2006-05-25 | ザ プロクター アンド ギャンブル カンパニー | クレンジング相と、油中水型エマルションを含む分離した効能相とを含有する、ストライプ模様の液体パーソナルクレンジング組成物 |
| PT1654261E (pt) * | 2003-05-21 | 2008-01-18 | Boehringer Ingelheim Int | Compostos inibidores da hepatite c |
| TW201127828A (en) * | 2003-09-05 | 2011-08-16 | Vertex Pharma | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease |
| EP1664091A1 (en) * | 2003-09-18 | 2006-06-07 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases, particularly hcv ns3-ns4a protease |
| CA2541634A1 (en) * | 2003-10-10 | 2005-04-28 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases, particularly hcv ns3-ns4a protease |
| AU2005212257A1 (en) * | 2004-02-04 | 2005-08-25 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease |
| AR055395A1 (es) * | 2005-08-26 | 2007-08-22 | Vertex Pharma | Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c |
-
2004
- 2004-10-08 CA CA002541634A patent/CA2541634A1/en not_active Abandoned
- 2004-10-08 KR KR1020067006901A patent/KR20060130027A/ko not_active Application Discontinuation
- 2004-10-08 KR KR1020117029638A patent/KR20120010278A/ko not_active Application Discontinuation
- 2004-10-08 AU AU2004282148A patent/AU2004282148A1/en not_active Abandoned
- 2004-10-08 MX MXPA06004006A patent/MXPA06004006A/es active IP Right Grant
- 2004-10-08 RU RU2006115558/04A patent/RU2006115558A/ru not_active Application Discontinuation
- 2004-10-08 EP EP04794554.8A patent/EP1692157B1/en active Active
- 2004-10-08 TW TW093130680A patent/TW200528472A/zh unknown
- 2004-10-08 JP JP2006534377A patent/JP2007532474A/ja active Pending
- 2004-10-08 NZ NZ546663A patent/NZ546663A/en not_active IP Right Cessation
- 2004-10-08 WO PCT/US2004/033238 patent/WO2005037860A2/en active Application Filing
- 2004-10-08 CN CN201010183514A patent/CN101857631A/zh active Pending
- 2004-10-08 EP EP10183579A patent/EP2361925A1/en not_active Withdrawn
- 2004-10-12 US US10/964,214 patent/US7208600B2/en not_active Expired - Fee Related
-
2006
- 2006-04-09 IL IL174863A patent/IL174863A0/en unknown
- 2006-05-10 NO NO20062101A patent/NO20062101L/no unknown
-
2007
- 2007-03-09 US US11/716,248 patent/US8039623B2/en not_active Expired - Fee Related
-
2011
- 2011-08-18 JP JP2011179106A patent/JP2011246487A/ja active Pending
Patent Citations (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994014436A1 (en) | 1992-12-29 | 1994-07-07 | Abbott Laboratories | Retroviral protease inhibiting compounds |
| WO1995007696A1 (en) | 1993-09-13 | 1995-03-23 | Abbott Laboratories | Pharmaceutical composition of hiv-protease inhibitors |
| US5948436A (en) | 1993-09-13 | 1999-09-07 | Abbott Laboratories | Pharmaceutical composition |
| WO1995009614A1 (en) | 1993-10-01 | 1995-04-13 | Abbott Laboratories | Pharmaceutical composition |
| US5484801A (en) | 1994-01-28 | 1996-01-16 | Abbott Laboratories | Pharmaceutical composition for inhibiting HIV protease |
| EP0675112A1 (en) | 1994-03-31 | 1995-10-04 | Bristol-Myers Squibb Company | Imidazole-containing inhibitors of farnesyl protein transferase |
| US6037157A (en) | 1995-06-29 | 2000-03-14 | Abbott Laboratories | Method for improving pharmacokinetics |
| US6344465B1 (en) | 1996-04-23 | 2002-02-05 | Vertex Pharmaceuticals, Incorporated | Inhibitors of IMPDH enzyme |
| WO1997040028A1 (en) | 1996-04-23 | 1997-10-30 | Vertex Pharmaceuticals Incorporated | Urea derivatives as inhibitors of impdh enzyme |
| US5807876A (en) | 1996-04-23 | 1998-09-15 | Vertex Pharmaceuticals Incorporated | Inhibitors of IMPDH enzyme |
| US6541496B1 (en) | 1996-04-23 | 2003-04-01 | Vertex Pharmaceuticals Incorporated | Inhibitors of IMPDH enzyme |
| US6054472A (en) | 1996-04-23 | 2000-04-25 | Vertex Pharmaceuticals, Incorporated | Inhibitors of IMPDH enzyme |
| WO1998017679A1 (en) | 1996-10-18 | 1998-04-30 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease |
| WO1998040381A1 (en) | 1997-03-14 | 1998-09-17 | Vertex Pharmaceuticals Incorporated | Inhibitors of impdh enzyme |
| WO2000056331A1 (en) | 1999-03-19 | 2000-09-28 | Vertex Pharmaceuticals Incorporated | Inhibitors of impdh enzyme |
| US6498178B2 (en) | 1999-03-19 | 2002-12-24 | Vertex Pharmaceuticals Incorporated | Inhibitors of IMPDH enzyme |
| WO2002008244A2 (en) | 2000-07-21 | 2002-01-31 | Schering Corporation | Peptides as ns3-serine protease inhibitors of hepatitis c virus |
| WO2002018369A2 (en) | 2000-08-31 | 2002-03-07 | Eli Lilly And Company | Peptidomimetic protease inhibitors |
| WO2003006490A1 (en) | 2001-07-11 | 2003-01-23 | Vertex Pharmaceuticals Incorporated | Bridged bicyclic serine protease inhibitors |
| WO2003035060A1 (en) | 2001-10-24 | 2003-05-01 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine protease, particularly hepatitis c virus ns3-ns4a protease, incorporating a fused ring system |
| WO2003087092A2 (en) | 2002-04-11 | 2003-10-23 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases, particularly hepatitis c virus ns3 - ns4 protease |
| WO2004092612A1 (de) | 2003-04-04 | 2004-10-28 | Zf Boge Elastmetall Gmbh | Hydraulisch dämpfendes gummibuchsenlager für vertikale montage |
| WO2004092161A1 (en) | 2003-04-11 | 2004-10-28 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases, particularly hcv ns3-ns4a protease |
| US7109172B2 (en) * | 2003-07-18 | 2006-09-19 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease |
Non-Patent Citations (39)
Cited By (125)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090143312A1 (en) * | 1996-10-18 | 2009-06-04 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease |
| US8314141B2 (en) | 1996-10-18 | 2012-11-20 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases, particularly hepatitis C virus NS3 protease |
| US7494988B2 (en) | 2000-04-03 | 2009-02-24 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases, particularly hepatitis C virus NS3 protease |
| US20030236242A1 (en) * | 2000-04-03 | 2003-12-25 | Robert Perni | Inhibitors of serine proteases, particularly hepatitis C virus NS3 protease |
| US8529882B2 (en) | 2000-08-31 | 2013-09-10 | Vertex Pharmaceuticals Incorporated | Peptidomimetic protease inhibitors |
| US20050197299A1 (en) * | 2000-08-31 | 2005-09-08 | Babine Robert E. | Peptidomimetic protease inhibitors |
| US7820671B2 (en) | 2000-08-31 | 2010-10-26 | Vertex Pharmaceuticals Incorporated | Peptidomimetic protease inhibitors |
| US20100137583A1 (en) * | 2000-08-31 | 2010-06-03 | Robert Edward Babine | Peptidomimetic protease inhibitors |
| US8252923B2 (en) | 2000-08-31 | 2012-08-28 | Vertex Pharmaceuticals Incorporated | Peptidomimetic protease inhibitors |
| US8691758B2 (en) | 2003-07-18 | 2014-04-08 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease |
| US20060211629A1 (en) * | 2003-07-18 | 2006-09-21 | Britt Shawn D | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease |
| US20110104115A1 (en) * | 2003-09-05 | 2011-05-05 | Vertex Pharmaceuticals Incoroprated | Inhibitors of serine proteases, particularly hcv ns3-ns4a protease |
| US8217048B2 (en) | 2003-09-05 | 2012-07-10 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease |
| US20080311079A1 (en) * | 2003-09-05 | 2008-12-18 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease |
| US7745444B2 (en) | 2003-09-05 | 2010-06-29 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease |
| US7365092B2 (en) | 2003-10-10 | 2008-04-29 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease |
| US8039623B2 (en) * | 2003-10-10 | 2011-10-18 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease |
| US20050080017A1 (en) * | 2003-10-10 | 2005-04-14 | Cottrell Kevin M. | Inhibitors of serine proteases, particularly HVC NS3-NS4A protease |
| US20070161789A1 (en) * | 2003-10-10 | 2007-07-12 | Cottrell Kevin M | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease |
| US20090105471A1 (en) * | 2003-10-14 | 2009-04-23 | Blatt Lawrence M | Macrocyclic compounds as inhibitors of viral replication |
| US20090111982A1 (en) * | 2003-10-14 | 2009-04-30 | Blatt Lawrence M | Macrocyclic compounds as inhibitors of viral replication |
| US20090111969A1 (en) * | 2003-10-14 | 2009-04-30 | Blatt Lawrence M | Macrocyclic compounds as inhibitors of viral replication |
| US7491794B2 (en) | 2003-10-14 | 2009-02-17 | Intermune, Inc. | Macrocyclic compounds as inhibitors of viral replication |
| US20060003942A1 (en) * | 2003-10-27 | 2006-01-05 | Roger Tung | Combinations for HCV treatment |
| US20120114604A1 (en) * | 2003-10-27 | 2012-05-10 | Vertex Pharmaceuticals Incorporated | Combinations for HCV Treatment |
| US8536136B2 (en) | 2004-02-04 | 2013-09-17 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease |
| US7683033B2 (en) | 2004-02-04 | 2010-03-23 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease |
| US20100330109A1 (en) * | 2004-02-04 | 2010-12-30 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases, particularly hcv ns3-ns4a protease |
| US20050215486A1 (en) * | 2004-02-04 | 2005-09-29 | Kevin Cottrell | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease |
| US20090148407A1 (en) * | 2005-07-25 | 2009-06-11 | Intermune, Inc. | Novel Macrocyclic Inhibitors of Hepatitis C Virus Replication |
| US8299021B2 (en) | 2005-07-25 | 2012-10-30 | Intermune, Inc. | Macrocyclic inhibitors of hepatitis C virus replication |
| US20070054842A1 (en) * | 2005-07-25 | 2007-03-08 | Blatt Lawrence M | Novel macrocyclic inhibitors of hepatitis C virus replication |
| US7829665B2 (en) | 2005-07-25 | 2010-11-09 | Intermune, Inc. | Macrocyclic inhibitors of hepatitis C virus replication |
| US20110171175A1 (en) * | 2005-08-02 | 2011-07-14 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases |
| US8871904B2 (en) | 2005-08-19 | 2014-10-28 | Vertex Pharmaceuticals Incorporated | Processes and intermediates |
| US20110182856A1 (en) * | 2005-08-26 | 2011-07-28 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases |
| US8372873B2 (en) | 2005-08-26 | 2013-02-12 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases |
| US7985762B2 (en) | 2005-08-26 | 2011-07-26 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases |
| US8440706B2 (en) | 2005-08-26 | 2013-05-14 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases |
| US20110165120A1 (en) * | 2005-08-26 | 2011-07-07 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases |
| US20070179167A1 (en) * | 2005-08-26 | 2007-08-02 | Cottrell Kevin M | Inhibitors of serine proteases |
| US7964624B1 (en) | 2005-08-26 | 2011-06-21 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases |
| US8119592B2 (en) | 2005-10-11 | 2012-02-21 | Intermune, Inc. | Compounds and methods for inhibiting hepatitis C viral replication |
| US8247532B2 (en) | 2006-03-16 | 2012-08-21 | Vertex Pharmaceuticals Incorporated | Deuterated hepatitis C protease inhibitors |
| US20080019942A1 (en) * | 2006-07-05 | 2008-01-24 | Intermune, Inc | Novel inhibitors of hepatitis c virus replication |
| US20100209391A1 (en) * | 2006-07-05 | 2010-08-19 | Intermune, Inc. | Novel inhibitors of hepatitis c virus replication |
| US7781474B2 (en) | 2006-07-05 | 2010-08-24 | Intermune, Inc. | Inhibitors of hepatitis C virus replication |
| US8575208B2 (en) | 2007-02-27 | 2013-11-05 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases |
| US20100272681A1 (en) * | 2007-02-27 | 2010-10-28 | Vertex Pharmaceuticals Incorporated | Inhibitors of Serine Proteases |
| US20090155209A1 (en) * | 2007-05-03 | 2009-06-18 | Blatt Lawrence M | Novel macrocyclic inhibitors of hepatitis c virus replication |
| US7932277B2 (en) | 2007-05-10 | 2011-04-26 | Intermune, Inc. | Peptide inhibitors of hepatitis C virus replication |
| US20090104001A1 (en) * | 2007-10-19 | 2009-04-23 | Kochheiser Michael A | Non-dimpling fastener |
| US9694086B2 (en) | 2007-12-21 | 2017-07-04 | Celgene Car Llc | HCV protease inhibitors and uses thereof |
| US20100069294A1 (en) * | 2007-12-21 | 2010-03-18 | Avila Therapeutics, Inc. | Hcv protease inhibitors and uses thereof |
| US8778877B2 (en) | 2007-12-21 | 2014-07-15 | Celgene Avilomics Research, Inc. | HCV protease inhibitors and uses thereof |
| US8293705B2 (en) | 2007-12-21 | 2012-10-23 | Avila Therapeutics, Inc. | HCV protease inhibitors and uses thereof |
| US8741837B2 (en) | 2007-12-21 | 2014-06-03 | Celgene Avilomics Research, Inc. | HCV protease inhibitors and uses thereof |
| US9676785B2 (en) | 2007-12-21 | 2017-06-13 | Celgene Car Llc | HCV protease inhibitors and uses thereof |
| US9163061B2 (en) | 2007-12-21 | 2015-10-20 | Celgene Avilomics Research, Inc. | HCV protease inhibitors and uses thereof |
| US20090176858A1 (en) * | 2007-12-21 | 2009-07-09 | Avila Therapeutics, Inc. | Hcv protease inhibitors and uses thereof |
| US8309685B2 (en) | 2007-12-21 | 2012-11-13 | Celgene Avilomics Research, Inc. | HCV protease inhibitors and uses thereof |
| US8003659B2 (en) | 2008-02-04 | 2011-08-23 | Indenix Pharmaceuticals, Inc. | Macrocyclic serine protease inhibitors |
| US8093379B2 (en) | 2008-02-04 | 2012-01-10 | Idenix Pharmaceuticals, Inc. | Macrocyclic serine protease inhibitors |
| US20100016578A1 (en) * | 2008-02-04 | 2010-01-21 | Idenix Pharmaceuticals, Inc. | Macrocyclic serine protease inhibitors |
| WO2009099596A2 (en) | 2008-02-04 | 2009-08-13 | Idenix Pharamaceuticals, Inc. | Macrocyclic serine protease inhibitors |
| US20090269305A1 (en) * | 2008-04-15 | 2009-10-29 | Intermune, Inc. | Novel macrocyclic inhibitors of hepatitis c virus replication |
| US8048862B2 (en) | 2008-04-15 | 2011-11-01 | Intermune, Inc. | Macrocyclic inhibitors of hepatitis C virus replication |
| EP2476690A1 (en) | 2008-07-02 | 2012-07-18 | IDENIX Pharmaceuticals, Inc. | Compounds and pharmaceutical compositions for the treatment of viral infections |
| US20100169023A1 (en) * | 2008-12-30 | 2010-07-01 | Searete Llc, A Limited Liability Corporation Of State Of Delaware | Computational methods and systems for suggesting modulators of CYP450 as treatment options |
| US8073633B2 (en) | 2008-12-30 | 2011-12-06 | The Invention Science Fund I, Llc | Computational methods and systems for suggesting modulators of CYP450 as treatment options |
| US8315815B2 (en) | 2008-12-30 | 2012-11-20 | The Invention Science Fund I, Llc | Computational methods and systems for suggesting modulators of CYP450 as treatment options |
| US8073632B2 (en) | 2008-12-30 | 2011-12-06 | The Invention Science Fund I, Llc | Computational methods and systems for treatment in relation to modulation of CYP450 enzyme activity |
| US8321151B2 (en) | 2008-12-30 | 2012-11-27 | The Invention Science Fund I, Llc | Computational methods and systems for treatment in relation to modulation of CYP450 enzyme activity |
| US20100169022A1 (en) * | 2008-12-30 | 2010-07-01 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Computational methods and systems for treatment in relation to modulation of CYP450 enzyme activity |
| US20100195379A1 (en) * | 2009-02-02 | 2010-08-05 | Qualcomm Incorporated | System and Method of Pulse Generation |
| US8735345B2 (en) | 2009-02-27 | 2014-05-27 | Hoffmann La Roche Inc. | Therapeutic composition |
| US20100221217A1 (en) * | 2009-02-27 | 2010-09-02 | Intermune, Inc. | Therapeutic composition |
| WO2010101967A2 (en) | 2009-03-04 | 2010-09-10 | Idenix Pharmaceuticals, Inc. | Phosphothiophene and phosphothiazole hcv polymerase inhibitors |
| US8377962B2 (en) | 2009-04-08 | 2013-02-19 | Idenix Pharmaceuticals, Inc. | Macrocyclic serine protease inhibitors |
| US8993595B2 (en) | 2009-04-08 | 2015-03-31 | Idenix Pharmaceuticals, Inc. | Macrocyclic serine protease inhibitors |
| WO2011017389A1 (en) | 2009-08-05 | 2011-02-10 | Idenix Pharmaceuticals, Inc. | Macrocyclic serine protease inhibitors useful against viral infections, particularly hcv |
| US9284307B2 (en) | 2009-08-05 | 2016-03-15 | Idenix Pharmaceuticals Llc | Macrocyclic serine protease inhibitors |
| US20110081315A1 (en) * | 2009-09-28 | 2011-04-07 | Intermune, Inc. | Novel macrocyclic inhibitors of hepatitis c virus replication |
| WO2011063076A1 (en) | 2009-11-19 | 2011-05-26 | Itherx Pharmaceuticals, Inc. | Methods of treating hepatitis c virus with oxoacetamide compounds |
| WO2011075615A1 (en) | 2009-12-18 | 2011-06-23 | Idenix Pharmaceuticals, Inc. | 5,5-fused arylene or heteroarylene hepatitis c virus inhibitors |
| WO2011123586A1 (en) | 2010-04-01 | 2011-10-06 | Idenix Pharmaceuticals, Inc. | Compounds and pharmaceutical compositions for the treatment of viral infections |
| US9353100B2 (en) | 2011-02-10 | 2016-05-31 | Idenix Pharmaceuticals Llc | Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating HCV infections |
| WO2012109398A1 (en) | 2011-02-10 | 2012-08-16 | Idenix Pharmaceuticals, Inc. | Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating hcv infections |
| US9243025B2 (en) | 2011-03-31 | 2016-01-26 | Idenix Pharmaceuticals, Llc | Compounds and pharmaceutical compositions for the treatment of viral infections |
| WO2012154321A1 (en) | 2011-03-31 | 2012-11-15 | Idenix Pharmaceuticals, Inc. | Compounds and pharmaceutical compositions for the treatment of viral infections |
| WO2012135581A1 (en) | 2011-03-31 | 2012-10-04 | Idenix Pharmaceuticals, Inc. | Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor |
| US8951985B2 (en) | 2011-09-12 | 2015-02-10 | Idenix Pharmaceuticals, Inc. | Compounds and pharmaceutical compositions for the treatment of viral infections |
| WO2013039855A1 (en) | 2011-09-12 | 2013-03-21 | Idenix Pharmaceuticals, Inc. | Compounds and pharmaceutical compositions for the treatment of viral infections |
| WO2013039920A1 (en) | 2011-09-12 | 2013-03-21 | Idenix Pharmaceuticals, Inc. | Substituted carbonyloxymethylphosphoramidate compounds and pharmaceutical compositions for the treatment of viral infections |
| WO2013056046A1 (en) | 2011-10-14 | 2013-04-18 | Idenix Pharmaceuticals, Inc. | Substituted 3',5'-cyclic phosphates of purine nucleotide compounds and pharmaceutical compositions for the treatment of viral infections |
| EP3750544A2 (en) | 2011-11-30 | 2020-12-16 | Emory University | Jak inhibitors for use in the prevention or treatment of viral infection |
| WO2013133927A1 (en) | 2012-02-13 | 2013-09-12 | Idenix Pharmaceuticals, Inc. | Pharmaceutical compositions of 2'-c-methyl-guanosine, 5'-[2-[(3-hydroxy-2,2-dimethyl-1-oxopropyl)thio]ethyl n-(phenylmethyl)phosphoramidate] |
| WO2013177195A1 (en) | 2012-05-22 | 2013-11-28 | Idenix Pharmaceuticals, Inc. | 3',5'-cyclic phosphate prodrugs for hcv infection |
| WO2013177219A1 (en) | 2012-05-22 | 2013-11-28 | Idenix Pharmaceuticals, Inc. | D-amino acid compounds for liver disease |
| WO2013177188A1 (en) | 2012-05-22 | 2013-11-28 | Idenix Pharmaceuticals, Inc. | 3',5'-cyclic phosphoramidate prodrugs for hcv infection |
| WO2014058801A1 (en) | 2012-10-08 | 2014-04-17 | Idenix Pharmaceuticals, Inc. | 2'-chloro nucleoside analogs for hcv infection |
| WO2014063019A1 (en) | 2012-10-19 | 2014-04-24 | Idenix Pharmaceuticals, Inc. | Dinucleotide compounds for hcv infection |
| WO2014066239A1 (en) | 2012-10-22 | 2014-05-01 | Idenix Pharmaceuticals, Inc. | 2',4'-bridged nucleosides for hcv infection |
| WO2014078427A1 (en) | 2012-11-14 | 2014-05-22 | Idenix Pharmaceuticals, Inc. | D-alanine ester of rp-nucleoside analog |
| WO2014078436A1 (en) | 2012-11-14 | 2014-05-22 | Idenix Pharmaceuticals, Inc. | D-alanine ester of sp-nucleoside analog |
| WO2014099941A1 (en) | 2012-12-19 | 2014-06-26 | Idenix Pharmaceuticals, Inc. | 4'-fluoro nucleosides for the treatment of hcv |
| WO2014137926A1 (en) | 2013-03-04 | 2014-09-12 | Idenix Pharmaceuticals, Inc. | 3'-deoxy nucleosides for the treatment of hcv |
| WO2014137930A1 (en) | 2013-03-04 | 2014-09-12 | Idenix Pharmaceuticals, Inc. | Thiophosphate nucleosides for the treatment of hcv |
| WO2014165542A1 (en) | 2013-04-01 | 2014-10-09 | Idenix Pharmaceuticals, Inc. | 2',4'-fluoro nucleosides for the treatment of hcv |
| WO2014197578A1 (en) | 2013-06-05 | 2014-12-11 | Idenix Pharmaceuticals, Inc. | 1',4'-thio nucleosides for the treatment of hcv |
| WO2015017713A1 (en) | 2013-08-01 | 2015-02-05 | Idenix Pharmaceuticals, Inc. | D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease |
| WO2015042375A1 (en) | 2013-09-20 | 2015-03-26 | Idenix Pharmaceuticals, Inc. | Hepatitis c virus inhibitors |
| WO2015061683A1 (en) | 2013-10-25 | 2015-04-30 | Idenix Pharmaceuticals, Inc. | D-amino acid phosphoramidate and d-alanine thiophosphoramidate pronucleotides of nucleoside compounds useful for the treatment of hcv |
| WO2015066370A1 (en) | 2013-11-01 | 2015-05-07 | Idenix Pharmaceuticals, Inc. | D-alanine phosphoramidate pronucleotides of 2'-methyl 2'-fluoro guanosine nucleoside compounds for the treatment of hcv |
| WO2015081297A1 (en) | 2013-11-27 | 2015-06-04 | Idenix Pharmaceuticals, Inc. | 2'-dichloro and 2'-fluoro-2'-chloro nucleoside analogues for hcv infection |
| WO2015095419A1 (en) | 2013-12-18 | 2015-06-25 | Idenix Pharmaceuticals, Inc. | 4'-or nucleosides for the treatment of hcv |
| WO2015134780A1 (en) | 2014-03-05 | 2015-09-11 | Idenix Pharmaceuticals, Inc. | Solid prodrug forms of 2'-chloro-2'-methyl uridine for hcv |
| WO2015134561A1 (en) | 2014-03-05 | 2015-09-11 | Idenix Pharmaceuticals, Inc. | Pharmaceutical compositions comprising a 5,5-fused heteroarylene flaviviridae inhibitor and their use for treating or preventing flaviviridae infection |
| WO2015134560A1 (en) | 2014-03-05 | 2015-09-11 | Idenix Pharmaceuticals, Inc. | Solid forms of a flaviviridae virus inhibitor compound and salts thereof |
| WO2015161137A1 (en) | 2014-04-16 | 2015-10-22 | Idenix Pharmaceuticals, Inc. | 3'-substituted methyl or alkynyl nucleosides for the treatment of hcv |
| US9815850B2 (en) | 2016-02-05 | 2017-11-14 | Denali Therapeutics Inc. | Compounds, compositions and methods |
| US9896458B2 (en) | 2016-02-05 | 2018-02-20 | Denali Therapeutics Inc. | Compounds, compositions and methods |
| US10131676B2 (en) | 2016-02-05 | 2018-11-20 | Denali Therapeutics Inc. | Compounds, compositions and methods |
| US10604535B2 (en) | 2016-02-05 | 2020-03-31 | Denali Therapeutics Inc. | Compounds, compositions and methods |
| US11072618B2 (en) | 2016-12-09 | 2021-07-27 | Denali Therapeutics Inc. | Compounds, compositions and methods |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2011246487A (ja) | 2011-12-08 |
| NO20062101L (no) | 2006-07-05 |
| WO2005037860A3 (en) | 2005-11-10 |
| RU2006115558A (ru) | 2007-11-20 |
| KR20120010278A (ko) | 2012-02-02 |
| EP1692157A2 (en) | 2006-08-23 |
| US20050137140A1 (en) | 2005-06-23 |
| MXPA06004006A (es) | 2006-06-28 |
| CN101857631A (zh) | 2010-10-13 |
| NZ546663A (en) | 2010-01-29 |
| AU2004282148A1 (en) | 2005-04-28 |
| US8039623B2 (en) | 2011-10-18 |
| EP2361925A1 (en) | 2011-08-31 |
| CA2541634A1 (en) | 2005-04-28 |
| EP1692157B1 (en) | 2013-04-17 |
| WO2005037860A2 (en) | 2005-04-28 |
| JP2007532474A (ja) | 2007-11-15 |
| US20070161789A1 (en) | 2007-07-12 |
| IL174863A0 (en) | 2008-02-09 |
| KR20060130027A (ko) | 2006-12-18 |
| TW200528472A (en) | 2005-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7208600B2 (en) | Inhibitors of serine proteases, particularly HCV NS3-NS4A proteases | |
| US7683033B2 (en) | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease | |
| US8426359B2 (en) | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease | |
| US7378422B2 (en) | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease | |
| AU2012202822A1 (en) | Inhibitors of Serine Proteases, Particularly HCV NS3-NS4A Protease | |
| AU2011253940A1 (en) | Inhibitors of serine proteases, particularly hcv ns3-ns4a protease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AS | Assignment |
Owner name: VERTEX PHARMACEUTICALS INCORPORATED, MASSACHUSETTS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:COTTRELL, KEVIN;PERNI, ROBERT;PITLIK, JANOS;REEL/FRAME:018331/0914;SIGNING DATES FROM 20060807 TO 20060822 |
|
| FPAY | Fee payment |
Year of fee payment: 4 |
|
| AS | Assignment |
Owner name: MACQUARIE US TRADING LLC, NEW YORK Free format text: SECURITY INTEREST;ASSIGNORS:VERTEX PHARMACEUTICALS INCORPORATED;VERTEX PHARMACEUTICALS (SAN DIEGO) LLC;REEL/FRAME:033292/0311 Effective date: 20140709 |
|
| REMI | Maintenance fee reminder mailed | ||
| LAPS | Lapse for failure to pay maintenance fees | ||
| STCH | Information on status: patent discontinuation |
Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362 |
|
| FP | Lapsed due to failure to pay maintenance fee |
Effective date: 20150424 |
|
| AS | Assignment |
Owner name: VERTEX PHARMACEUTICALS (SAN DIEGO) LLC, CALIFORNIA Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:MACQUARIE US TRADING LLC;REEL/FRAME:040357/0001 Effective date: 20161013 Owner name: VERTEX PHARMACEUTICALS INCORPORATED, MASSACHUSETTS Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:MACQUARIE US TRADING LLC;REEL/FRAME:040357/0001 Effective date: 20161013 |